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Abstract 
 
Strangles is caused by host restricted pathogen Streptococcus equi subspecies equi 
(S. equi) and is the most frequently diagnosed equine disease. This highly 
contiguous disease accounts for approximate 30% of recorded incidents of equine 
disease annually (Harrington, Sutcliffe, & Chanter, 2002). Strangles is 
characterized by abscessation of the lymph nodes of the head and neck. The 
severity of this disease varies largely depending on the immune status of the 
affected animal (Sweeney et al., 2005). Diagnosis of strangles can be complicated 
by the presence of other beta haemolytic streptococci, especially the closely 
related S. zooepidemicus. Moreover, the current method used to detect S. equi in 
the carriage state – via samples from the guttural pouches of apparently healthy 
horses after recovery from strangles - is not always practical.  
 
Currently there are two vaccines for strangles available in NZ. One is a non-
encapsulated and attenuated strain of S. equi, Pinnacle
®
 IN (Ford Dodge, USA), 
which is administered intranasally. Another is an inactivated bacterin, Equivac
®
 S 
(Pfizer, NZ), used intramuscularly. However, the efficacy of these two vaccines to 
the three NZ S. equi strains is not clear. Also the level of induced antibodies with 
the sera of inoculated animals is unkown.  
 
In this study, an enzyme-linked immuno-sorbent assay (ELISA) and an indirect 
fluorescent-antibody assay (IFA) were developed to detect specific antibodies in 
sera from horses either infected with S. equi, or vaccinated with Pinnacle or 
Equivac S, or unvaccinated. Four peptides synthesized by GenScript (GenScript, 
USA) were used for the ELISA study. Of these, three peptides targeted the N-
terminal variable regions of S. equi strains 99, 100 and the vaccine strain. The 
other was a PEPK repeats peptide, corresponding to a region present in the N-
terminal region of the S. equi protein SzPSe. Both ELISA and IFA results showed 
that relatively high levels of antibodies were induced following vaccination or 
infection. Also, the induced antibodies demonstrated cross-reactivity to all three S. 
equi strains tested. ELISA for the PEPK peptide produced higher ODs than seen 
with the three SeM peptides, suggesting that there were more antibodies against 
PEPK peptide within the sera. The IFA results showed a difference in titre 
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between pre-vaccinated horses and post-vaccinated horses; whilst the ELISA 
results did not. This may be due to serological reactivity between those four 
peptides and ‘natural antibodies’ induced by exposure to the closely related S. 
zooepidemicus. Further evidence in support of this result was seen in western 
blotting, which showed that ‘natural antibodies’ in serum from pre-vaccinated 
horses reacted serologically with proteins from S. equi. IFA was shown to be the 
better method for the diagnosis of strangles and for the study of the antibody 
responses after vaccination or infection. 
 
ELISA and IFA results also showed that the observed antibody levels induced by 
Pinnacle and Equivac S were similar, indicating the comparable efficacy of these 
two vaccines. All of the vaccinated horses had high levels of pre-existing 
antibodies within their sera, even one year after vaccination. This may suggest 
that an increase in the interval of booster time could be acceptable. However, it is 
acknowledged that antibody titres do not necessarily equal protection from 
infection. Western blotting results indicated that a stronger immunity was formed 
after natural infection than seen in horses after. This is because after infection the 
entire immune system (both humoral and cell-mediated) will be stimulated.  
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Chapter One 
Introduction and Literature Review 
 
 
1.1 Strangles 
 
Strangles caused by host restricted pathogen Streptococcus equi subspecies equi 
(S. equi) is the most frequently diagnosed disease of horses. This highly 
contiguous disease accounts for approximate 30% of recorded incidents of equine 
disease annually (Harrington, Sutcliffe, & Chanter, 2002) . In 2008 an audit of 
strangles in the UK reported more than 700 outbreaks (Ivens et al., 2011). It is 
noteworthy that over 200 horses were infected in some of these outbreaks, which 
led to significant welfare and economic costs (Ivens et al., 2011).  
 
Strangles is characterized by abscessation of the lymph nodes of the head and 
neck. The severity of this disease varies largely depending on the animal’s 
immune status (Sweeney et al., 2005). Whereas old horses normally present a 
mild form of the disease, showing nasal discharge, small abscesses, and rapid 
recovery; young horses usually develop severe swelling of lymph nodes with 
subsequent abruption (Sweeney et al., 2005). 
 
Fever is the first clinical sign of strangles. Within 24 hours of onset of fever, the 
affected horses commonly become anorexic, listless, and depressed (Sweeney et 
al., 2005; Taylor et al., 2006). Bilateral nasal discharge can occur at the same time 
and rapidly becomes mucopurulent (Fig. 1.1). Increases in plasma fibrinogen 
concentration and leukocyte counts can be detected at this time. Abscessation of 
submandibular and retropharyngeal lymph nodes may occur about seven days 
after infection (Fig. 1.2). The horse may overextend its neck to achieve respiration 
if the swelling blocks the airflow in the upper respiratory tract; hence the name 
strangles of this disease. Tracheotomy is sometimes necessary for severely 
affected horses. Rupture of the abscessed lymph nodes typically occurs 7 to 10 
days after the onset of clinical signs (Fig. 1.3) and recovery can be complete 
within 1 to 2 weeks after rupture. 
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Figure 1.1 Horse infected with clinical strangles showing purulent nasal discharge 
 
 
 
Figure 1.2 Horse with swollen submandibular and retropharyngeal lymph nodes 
caused by S. equi infection 
 
 
 
 
 
Figure 1.3 Rupture of submandibular lymph node abscesses 
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In some cases, during the early or febrile stage S. equi disseminates and forms 
abscesses in other parts of the horse body, such as lungs or abdominal lymph 
nodes. This condition often leads to death or euthanasia and is called ‘bastard 
strangles’. S. equi infection may also trigger the potentially fatal condition 
purpura haemorrhagica, which is an immune complex disease and capable of 
causing oedema (Pusterla et al., 2003; Waller and Jolley, 2007). 
 
Most of the horses fully recover after infection and can form a solid immunity. 
However, around 10% of the horses will become potential carriers. Those horses 
are referred to long-term, subclinical S. equi carriers, which can infect susceptible 
animals and be a source of new outbreaks. The well-recognized site for prolonged 
S. equi carriage is the guttural pouch, harbouring S. equi after rupture of 
retropharyngeal lymph nodes through the floor of the pouch (Timoney, 2004; 
Sweeney et al., 2005). ‘Chondroids’ may be formed when S. equi becomes 
inspissated in the guttural pouch and can be detected by endoscope. Subclinical 
inflammation of the host horse results from the high quantities of S. equi within 
chondroids (Verheyen et al., 2000). 
 
 
 
1.2 Streptococcus equi Subspecies equi (S. equi) 
 
S. equi is a host restricted pathogen and the causative agent of strangles. S. equi 
belongs to Lancefield group C streptococcus and has β-haemolytic activity on 
blood agar. It is distinguished from other streptococci by its inability to ferment 
lactose, sorbitol and trehalose because of lacking lacE, sorD and rbsD (Grant et 
al., 1993; Efstratiou et al., 1994; Holden et al., 2009).  
 
It is generally believed that S. equi evolved from the zoonotic pathogen 
streptococcus equi subspecies zooepidemicus (S. zooepidemicus) (Harrington et 
al., 2002; Jorm et al., 1994; Chanter et al., 1997; Webb et al., 2008; holden et al., 
2009). S. equi shares about 98% of DNA homology with S. zooepidemicus, an 
opportunistic pathogen infecting horses and other animals including human. 
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Genome-scale study indicated that both genomes are similar in size. The genome 
of S. equi (strain 4047) is 2,253,793 bp in length and S. zooepidemicus (strain H70) 
is 2,149,866 bp in length (Holden et al., 2009). However, S. equi (strain 4047) has 
more predicted coding sequences (2,137) compared to S. zooepidemicus (strain 
H70) (Holden et al., 2009). Moreover, the majority of the remaining non-
orthologous S. equi CDS (coding sequences) are found on mobile genetic 
elements which could explain the genome size increase of S. equi (Holden et al., 
2009). Additionally the genome of S. equi has more partially deleted genes and 
pseudogenes than that of S. zooepidemicus, displaying a degree of functional loss 
(Holden et al., 2009). Genome studies of S. equi, S. zooepidemicus and S. 
pyogenes provides evidence of horizontal genetic exchange, which has shaped the 
pathogenicity of these three bacteria (Holden et al., 2009). 
 
 
1.3 Virulence Factors of S. equi 
 
1.3.1 M-like protein 
 
The M protein was initially found in Streptococcus pyogenes (S. pyogenes) and 
described by Rebecca Lancefield in 1928 (Lancefield, 1928). M protein was used 
to discriminate S. pyogenes strains by serological analysis of a purified M protein 
fragment, which is called M typing. Today sequence analysis of the emm gene 
fragment coding for the primary antigenic region of M protein are widely used to 
distinguish different strains (Metzgar and Zampolli, 2011). 
 
S. equi possesses a similar protein on its cell surface, which is called M-like 
protein (SeM). SeM is the main virulence factor of S. equi with antiphagocytic 
property. Structural study showed that SeM formed a α-helical coiled-coil 
dimmers. SeM could bind both fibrinogen (Fb) through residues located at the 
extreme N-terminus of SeM and equine IgG-Fc with residues in the central region 
of SeM (fig. 4) (Meehan et al., 2001). Phagocytosis is blocked because of a 
reduction in deposition of C3b on the S equi cell surface due to binding of Fb by 
SeM.  
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Although originally it is postulated that SeM is invariant among S. equi strains 
(Galan & Timoney, 1988), a truncated M-like protein losing 20% of its N-
terminus (363-441 bp) was found from a persistent carrier animal (Chanter et al., 
2000). The N terminal end of SeM is now known to be highly variable and hence 
is used for SeM typing of S. equi (Fig. 1.4). 
 
 
 
Figure 1.4  Schematic representation of the SeM protein of S. equi. Amino acids 37 to 352 are 
required for fibrinogen binding. Amino acids 71 to 421 are the IgG binding region. Amino 
acids 37 to 184 were found deleted from some subclinical carriers. Amino acids 41 to 143 are 
used for sub-typing (SeM typing).  
  
 
1.3.2 Superantigens 
 
S. equi is hyperlysogenic to horses because it lacks the clustered regularly 
interspaced short palindromic repeat (CRISPR) locus, which confers resistance to 
phage attack and invading DNA (Barrangou et al., 2007; Holden et al., 2009; 
Sorek et al., 2008). A genome study of S. equi 4047 strain found four different 
superantigens- SeeH, SeeI, SeeM, SeeL (Holden et al., 2009). The prophage φSeq 
3 contains coding sequences for SeeM and SeeL, which are closely related to 
SpeL and SpeM of S. pyogenes serotype M18, sharing 99% and 98.1% DNA 
sequence homologies, respectively (Proft et al., 2003). φSeq 4 carries genes 
encoding SeeH and SeeI, which share 98% and 99% amino acid sequence 
similarities with SpeH and SpeI of S. pyogenes strain M1, respectively (Artiushin 
et al., 2002).     
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Superantigens are potent immune-stimulatory molecules which can stimulate 
nonspecific T-lymphocyte proliferation and generate an overzealous 
proinflammatory response, leading to the disruption of innate and adaptive 
immune responses (Llewelyn and Cohen, 2002; Sriskandan et al., 2007). 
Superantigens fulfil their functions by their abilities to disrupt the mechanism of 
major histocompatibility complex (MHC)–restricted antigen presentation 
(Dellabona et al., 1990). Traditionally, exogenous antigens are first recognized 
and processed by antigen-presenting cells (APC) within the antigen groove of 
MHC class II molecules. After that, they are presented to antigen-specific T-cell 
receptor (TCR), resulting in highly specific T-cell activation (1 in 1 X 10
6
 T 
lymphocytes activated) (Li et al., 1999; Llewelyn and Cohen, 2002). Interestingly, 
secreted superantigens directly bind to the MHC class II molecule outside the 
peptide-binding site as intact proteins and bind to one or more TCR Vβ chains. As 
a result, five to 20% of the T lymphocytes can be activated since there are limited 
numbers of different Vβ chains in the human T-cell repertoire. T-cell activation 
by superantigens results in the uncontrolled release of proinflammatory mediators 
and cytokines, including tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1) 
and IL-6, and gamma interferon (IFN-γ) (Norrby-Teglund et al., 1994). 
 
A very recent study found that activation of equine CD4 T lymphocytes and 
synthesis of IFN- γ by superantigens SeeI, SeeL and SeeM are dose-dependent 
(Paillot et al., 2010). Superantigen SeeH cannot induce proliferation of equine 
peripheral blood mononuclear cells (PBMC) but can stimulate asinine PBMC 
(Paillot et al., 2010). The mitogenic activity and synthesis of IFN- γ are 
completely abrogated by deletion of SeeI, seeL and seeM together (Paillot et al., 
2010).  
 
 
1.3.3 H factor binding protein - Se18.9 
 
Recently, a new virulence factor of S. equi was described and named as Se18.9, an 
18.9 kD protein. Se18.9 can bind factor H and inhibit phagocytosis by reducing 
C3 deposition on the bacterial surface (Tiwari et al., 2007). A polymerase chain 
reaction (PCR) study found that Se18.9 was produced by all 26 strains of S. equi 
examined, but by only 1 of 140 strains of S. zooepidemicus (Holden et al., 2009). 
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Only two SNP loci of Se18.9 were detected when 25 isolates of S. equi were 
screened, which means the selection pressure of the nasopharyngeal mucosal 
immune niche does not affect this gene (Ijaz et al., 2011).  
 
 
1.3.4 IgG endopeptidases  
 
One of the key elements in the immune system is immunoglobulin G (IgG). 
Several reactions like complement activation and phagocytosis by opsonisation 
could be boosted when IgG binds to an antigen. In order to evade recognition by 
IgG, several bacterial pathogens possess secreted extracellular enzymes which can 
interact with IgG (Hulting et al., 2009). One such enzyme secreted by S. equi is 
IdeE, a homolog of IdeZ and IdeS/Mac produced by S. zooepidemicus and S. 
pyogenes, respectively (Lannergard and Guss, 2006). IdeS is a cysteine protease 
which can cleave human IgG at the substrate site LLGGP (Lannergard and Guss, 
2006). Similarly, recombinant IdeE can digest a range of antibodies from horse, 
human, guinea-pig and dog but not pig. Interestingly, IdeE has the lowest 
efficiency against IgG of horse. One explanation is that more than 65% of the 
total IgG in horse serum is IgG4 which lacks a Leu-Leu-Gly motif. Endopeptidase 
activity can only be seen when bacteria grow in the presence of serum but not 
purified horse IgG (Lannergard and Guss, 2006).  
 
More recently, another IgG endopeptidase of S. equi, named IdeE2, has been 
found (Hulting et al., 2009). IdeE2 shows sequence similarity with IdeE and 
display high substrate-specificity compared with IdeE (Hulting et al., 2009).  
 
 
1.3.5 Sortase-processed cell envelope proteinase (SeCEP) 
 
SeCEP is a homolog of SpyCEP of S. pyogenes, which can cleave and inactivate 
interleukin 8 and other CXC chemokines (Edwards et al., 2005; Turner et al., 
2009). Dissemination of both S. pyogenes and S. equi was significantly reduced 
when mice were vaccinated with SpyCEP and later manually infected with those 
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two streptococci, indicating a cross-protection against streptococci producing 
those proteins when they are immunized with CEP (Turner et al., 2009).  
 
 
1.3.6 Collagen binding protein – CNE 
 
CNE is a sortase-processed cell surface protein which helps bacteria adhere to 
collagen (Lannergard et al., 2003). CNE is found in the genomes of every S. equi 
and S. zooepidemicus strain examined to date (Holden et al., 2009; Swierczynski 
et al., 2006; Lannergard et al., 2003), and is likely to be important for bacteria 
adhesion to host tissues like tonsillar epithelium (Waller et al., 2011). A new 
multi-competent recombinant vaccine containing recombinant CNE conferred 
high protection against S. equi infection in Welsh mountain ponies (6 of 7 ponies 
protected) and those ponies showed reduced symptoms compared with non-
vaccinated horses (Guess et al., 2009). 
 
 
1.3.7 Capsule 
 
A capsule is a layer outside the cell wall of bacteria. It consists of high molecular 
weight polymer of hyaluronic acid (HA), a polysaccharide with alternating 
residues of N-acetylglucosamine and glucuronic acid (Timoney, 2004). 
Encapsulated S. equi strains can form mucoid colonies when cultured in the 
presence of HA (Anzai et al., 1999). The capsule can help S. equi resistance to 
phagocytosis and can reduce the numbers of streptococci associated with the 
surface of neutrophils (Timoney, 2004).  The negative charge of the capsule and 
the hydrophilicity of the bacterial surface also produce a reducing environment, 
protecting the activity of oxygen-labile proteases and toxins like streptolysin S. 
 
The has operon is responsible for the synthesis of the capsule. This operon is 
composed of hyaluronate synthase (hasA) (DeAngelis, Papaconstantinou, & 
Weigel, 1993), UDP-glucose dehydrogenase (hasB) and UDP-glucose 
pyrophosphorylase (hasC) (Dougherty and Van de Rijn, 1994). 
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1.3.8 Fibronectin-binding Proteins – FNE, FNEB and SFS 
  
Members of this group of proteins can bind fibronectin, a dimeric glycoprotein 
found in the extracellular matrix and plasma of vertebrates (Lannergard, 2005). S. 
equi can produce three different kinds of fibronectin-binding proteins – FNE 
(Lindmark et al., 2001), SFS (landmark, 1999) and FNEB (Lannergard et al., 
2005).  
 
Horses infected with strangles have been shown to elicit a strong IgG antibody 
response to FNE, SFS and FNEB (Lannergard et al., 2005). A western blotting 
study showed that FNEB binds to the N-terminal 29-kDa fragment of fibronectin, 
however both FNE and SFS bind to the adjacent 40-kDa fragment. Inhibition 
studies proved that only FNEB mediates S. equi cells binding to fibronectin 
(Lannergard et al., 2005).  
 
 
1.4 Immune Response to Infection by S. equi 
 
Approximately 75% of infected horses can form a strong and lasting immunity to 
strangles after recovery from the disease (Todd, 1910; Hamlen et al., 1994). This 
developed immunity can last for at least 4 years to prevent horses from infection 
by S. equi (Todd, 1910; Hamlen et al., 1994). However, about 25% of horses fail 
to produce an adequate amount of the mucosal and systemic antibodies and are 
susceptible to a second attack of the disease within 6 to 12 months (Timony, 
1993). During convalescence, the horse’s immune system produces a strong 
serum IgGb response against surface exposed proteins, including SeM, Se44.2, 
Se46.8, Se45.5 and Se42.0 (Timony, 2004). Moreover, many horses can mount an 
opsonophagocytic serum IgGb specific response for the highly antiphagocytic and 
immunogenic SeM at late convalescence stage (Timony, 1985). In addition, SeM 
specific mucosal IgA and IgGb are induced during the acute and convalescent 
phases but not after intramuscular vaccination.    
 
Antibodies in nasal mucus and in serum of horses are independently induced after 
infection with S. equi. (Galan, 1985).  Only two major immunoglobin proteins 
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from mucus are detected and have no detectable reaction with proteins from S. 
equi culture supernatant (Galan, 1985). However, antibodies within serum can 
react with a range of culture supernatant proteins. The adhesion of S. equi to 
receptors on tonsillar cells could be prevented by mucosal antibodies, which may 
also hinder cell invasion of the organism after it adheres.  
 
Milk from mares recovered from strangles contains specific IgA and IgGb similar 
to those found in nasopharyngeal mucus of convalescent horses (Galan et al., 
1986). Those protective antibodies can benefit suckling foals until weaned. Foals 
suckling immune mares are usually resistant to S. equi infection until weaning.  
 
 
1.5 Diagnosis of strangles 
 
The following description of a diagnosis of strangles is based on a review paper 
(Timoney, 2004) and a consensus statement (Sweeney et al., 2005). Three 
strategies for diagnosis of strangles are discussed: culture, polymerase chain 
reaction (PCR), and serology. 
 
Culture of nasal swabs, nasal washes, or pus from abscesses on Columbia CNA 
(colistin, nalidixic acid) agar is critical for detection of S. equi. Culture results 
may be complicated by the presence of other beta haemolytic streptococci, 
especially S. zooepidemicus.  
 
Detection of small numbers of S. equi by nasal washes is more sensitive than via 
swabs because a larger surface area within the internal nares is sampled. However, 
culture may fail during the incubation and early clinical phases. Moreover, culture 
of nasal swabs or washes cannot detect S. equi when in the carriage state in 
guttural pouches of apparently healthy horses after recovery from strangles. The 
only way to identify these carriers is by endoscopic examination to confirm 
empyema and/or chondroids and to sample pouch content. However, this is not a 
routine screening measure practically.  
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Molecular techniques have also been designed to detect S. equi based on PCR 
(Alber et al., 2004; Anzai et al., 2006; Laus et al., 2007; Jannatabadi et al., 2008; 
Preziuso et al., 2010; Pusterla et al., 2011).  Generally, PCR methods are more 
sensitive than traditional culture methods. Moreover, PCR only needs couple of 
hours rather than a few days to confirm the presence of S. equi.  
 
Culture and PCR examinations are useful methods to detect S. equi, however there 
are some problems pertaining to the timing and methods of sampling, and the state 
and number of the bacteria observed. It is necessary to develop an accurate 
serological test to overcome some of these limitations and to provide a more 
sensitive diagnosis (Hobo et al., 2006). Initially the surface proteins obtained by 
the acid or enzyme extraction of S. equi for serological examination could cross-
react with S. zooepidemicus; therefore, serological tests are not suitable.  However, 
recently serological properties of the epitopes of the M-like proteins SeM and 
SzPSe of S.equi were studied (Hobo et al., 2006). One hundred and thirty one 16-
mer peptides for SeM and 91 16-mer peptides for SzPSe were synthesised over 
the whole peptide region with 12 amino acid overlap. ELISA studies showed that 
proline-glutamic acid-proline-lysine (PEPK) had strong reaction with IgG in the 
sera of horses infected with S. equi but reacted only minimally with the sera from 
the horses infected with S. zooepidemicus, indicating the PEPK repeats located in 
the C-terminal domain of SzPSe can be used as a potential antigen for the 
serological diagnosis of strangles. A further study (Hobo et al., 2008) illustrated 
that 5 PEPK repeats were optimal for an ELISA test. 
 
More recently a new serological test, developed by the Animal Health Trust 
(AHT), has become available in the UK. This ELISA detects IgG antibodies 
against two novel S. equi-specific antigens, revealing recent exposure to S. equi 
with a reported sensitivity of 91.5 percent and specificity of 90.5 percent. This test 
primarily detects recent exposure to S. equi but is also claimed to detect 
asymptomatic carriers with a sensitivity of 90.9 percent and a specificity of 82.6 
percent (AHT, 2008). 
 
 
1.6 Vaccines Against S. equi 
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Currently, there are two vaccines for strangles available in New Zealand. One is a 
non-encapsulated and attenuated strain of S. equi, Pinnacle
®
 IN (Ford Dodge, 
USA), used as an intranasal vaccine. It was first invented by Timoney in 1993 
(Timoney, 1993). This pinnacle vaccine is a modified strain of S. equi CF32. The 
vaccine strain is lacking a capsule due to chemical mutation of has genes by a 
methylating compound N-methyl-N’-nitro-N-nitrosoguanidine (NTG) and thus it 
forms small dry colonies rather than mucoid colonies on blood agar. Moreover, 
this strain has a 41,000 Dalton M protein fragment which can stimulate an 
immunological response to IgG and IgA antibodies in equine nasopharyngeal 
mucus. It has been used in North America since 1998 as an intranasal strangles 
vaccine. However, cultures of Pinnacle strain can sometimes reverse to mucoid 
and cannot be distinguished from wild strains of S. equi. An improved pinnacle 
vaccine with mutated has genes was developed later (Walker and Timoney, 2002). 
Unfortunately, Pinnacle® IN is known to have undesirable side effects and thus 
has not been licensed for sale in Europe due to safety concerns. 
  
Another vaccine is an inactivated bacterin, Equivac® S (Pfizer, NZ), used 
intramuscularly. It is also available with a tetanus vaccine, named Equivac® 2 in 
1. 
 
 
1.7 Serological Assay 
 
Serological assays are used to detect the presence of antibodies within serum 
samples against a microorganism. Certain microorganisms stimulate the body to 
produce antibodies during infection or the antibodies are stimulated by 
vaccination. 
 
1.7.1 Enzyme-linked Immunosorbent Assay (ELISA) 
 
ELISA is a plate-based assay which is designed for detecting and quantifying 
substances such as peptides, proteins, antibodies and hormones (Lequin, 
2005).  In an ELISA, an antigen must be immobilized on a solid surface and then 
complexed with an antibody which is linked to an enzyme. Detection is 
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accomplished by assessing the conjugated enzyme activity through incubation 
with a substrate to produce a measureable product (Lequin, 2005). The most 
crucial element of the detection strategy is that the antibody-antigen interaction 
should be highly specific. 
 
ELISA can be performed with a number of modifications to the basic procedure. 
The key step is to immobilize the antigen of interest. It can be accomplished by 
directly immobilizing to the assay plate or indirectly via a capture antibody that 
has been attached to the plate. Then the antigen can be detected either directly 
(labelled primary antibody) or indirectly (labelled secondary antibody). The most 
useful ELISA assay format is the sandwich assay (Lequin, 2005; Leng et al., 
2008). It is called a “sandwich” assay because the analyte to be measured is bound 
between two primary antibodies – the capture antibody and the detection antibody. 
The sandwich format is widely used because it is sensitive and robust (Lequin, 
2005). 
 
Also, an ELISA can be performed as a competitive assay (Lequin, 2005; Leng et 
al., 2008). This is a common method when the antigen is small and has only one 
antibody binding site, or only one epitope. One variation of this method is to use 
labelled antigen instead of the antibody. Unlabelled antigen from samples will 
compete with the labelled antigen for binding to the capture antibody. A decrease 
in signal indicates the presence of the antigen in samples when compared to assay 
wells with labelled antigen alone. 
 
In this study, three strain specific SeM peptides and PEPK peptide synthesized 
from Genscript were used to detect the peptide specific antibody levels within 
horse serum by ELISA study. 
 
1.7.2 Indirect Fluorescent-antibody Assay (IFA) 
 
Another commonly used serological assay is IFA, which is used to demonstrate 
the presence of antibodies against a specific antigen in serum. Antigen or the 
microorganism itself is incubated with a serum sample. Excess serum is washed 
away, leaving only antibodies specific for the antigen (or antigens of the 
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microorganism) present in the serum bound. The sample is then incubated with 
antibodies labelled with fluorescent dye that are specific for antibodies. The 
sample is then viewed with a fluorescent microscope.  
 
IFA is a widely used serological method for disease diagnosis, like tularaemia, 
spirochetal meningitis and cat scratch disease (Tsuneoka et al., 2004; Porsch-
Ozcurumez et al., 2004). However, until now there has not been any research on 
diagnosis of S. equi by IFA, although this technique has been used with 
Streptococcus pyogenes (Glurich et al., 1991). In this study, IFA was used to 
detect antibody levels within horse serum against S. equi to address the possibility 
of IFA as a diagnostic test of S. equi infection and also the efficacy of those two S. 
equi vaccines in inducing antibody responses.    
 
 
1.8 Hypothesis 
 
1. Horses will form antibodies against a natural infection of S. equi and 
vaccination. 
 
2. Antibodies will be general and cross-reacted with different strains.  
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Chapter Two 
 
Materials and Methods 
 
 
2.1  Blood Samples from Horses 
 
One hundred and thirty nine blood samples were submitted from collaborating 
veterinarians. Samples were from four different studs of New Zealand –stud S, W, 
A, and O. Blood samples were taken from naturally infected horses, horses prior 
to and post vaccination. Detailed information about these horses is in Appendix A. 
Generally, horses from stud S were named as No. SI-1 to SI-18. Horses from stud 
W were recorded as No. A to AA. Horses from stud A were recorded as No.1 to 
36. Horses from stud O were recorded as No. 36 to 44. 
 
Samples were received during the running of this course of this study between 
July 2012 and July 2013. Received blood samples were first centrifuged at 2500 
rpm for 15 minutes. Sera obtained from the upper phase were transferred into 1.5 
ml storage tubes, which were labelled and stored at - 80 
o
C. 
 
 
2.2  Indirect Fluorescent Assay (IFA)  
 
2.2.1 Preparation of Phosphate Buffered Saline (PBS) buffer 
 
PBS buffer was used to rinse cells during cell preparation. PBS buffer at pH 7.4 
was used because it is isotonic and non-toxic to cells; also, it helps wash off 
unbound proteins. To prepare 1 L of either 1X or 10X PBS, the reagents listed in 
table 2.1 were dissolved in 800 mL of distilled H2O. pH was adjusted to 7.4 with 
hydrochloric acid and then brought to 1 L with ddH2O. The solution was sterilized 
by autoclaving for 20 minutes and was stored at room temperature. 
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Table 2.1 Concentration of Chemicals in 1 L PBS Solution 
 
 
       
2.2.2 Preparation of PBS + 0.05% Tween 20 (PBS-T) 
 
PBS-T was used to wash slides while shaking. Tween 20 at concentration of 
0.05% to 0.1% (v/v) can disrupt low affinity non-specific interactions. To make 1 
L of PBS + 0.05% Tween 20, 500 uL of Tween 20 was added into 1 L of prepared 
PBS buffer. 
 
2.2.3 Preparation of PBS-T/Sodium Azide (NaAz) 
 
PBS-T/NaAz was used to dilute and preserve the horse sera. When mixed with 
water or an acid, NaAz can rapidly change to a toxic gas. In order to make 50 ml 
of PBS-T/NaAz, 50 uL of 10% NaAz was added into 50 mL of PBS-T. 
 
2.2.4 Preparation of FITC Conjugate for IFA 
 
The IgG antibody subtype is the most abundant serum immunoglobulin of the 
immune system. Anti-Horse IgG (whole molecule)-FITC antibody (Sigma, USA) 
specific for horse IgG subclasses was used for immunofluorescence. To make the 
conjugate for IFA, 10 uL of anti-horse IgG-FITC antibody and 10 uL of 1% 
Napthalene Black were added to 300 uL PBS-T/NaAz, giving a 1: 32 final 
dilution of the conjugate. 
 
2.2.5 Preparation of BHI (Brain Heart Infusion) + 1% YE (Yeast 
Extract) Broth 
 
BHI + 1% YE broth was used to culture S. equi cells for IFA and western blotting. 
BHI (Bacto™ Brain Heart Infusion, Difco) broth was made according to 
manufacturer’s directions. One percent YE (w/v) was then added and the broth 
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was sterilized by autoclaving. The BHI + 1% YE broth was stored in a fridge until 
further usage. 
 
2.2.6 Preparation of Blood Agar Plates 
 
Blood agar plates were used to culture S. equi. Columbia Blood Agar Base 
(Difco) was made according to manufacturer’s directions. The media was 
sterilized by autoclaving and then incubated in a water bath at 50 
o
C for at least 1 
hour. After adding 10% (v/v) sheep blood (Life Technologies) and gently mixed, 
media was poured into petri dishes (approximately 20 mL each). 
 
2.2.7 Preparation of S. equi Cells 
 
Two New Zealand S. equi strains (strains 99 and 100) and a vaccine strain 
(Pinnacle) were streaked on a blood agar plate followed by incubation at 37 
0
C for 
7 hours. After incubation, each S. equi strain culture was inoculated into a cell 
tissue culture flask (T25) having 10mL pre-warmed BHI + 1% YE broth and was 
shaking at 37 
o
C in a shaking incubator overnight. 
 
On the second day morning, each culture was poured into a labelled 15 mL falcon 
tube and centrifuged at 3000 rpm for 15 minutes. The supernatant was then tipped 
off carefully and the pellet was resuspended and washed with 5 mL PBS. After 
another centrifugation step (3000 rpm for 15 minutes), the supernatant was 
removed from each tube and the cell pellet was resuspended with 10 mL PBS. 
Cells were then thoroughly vortexed in order to break up clumps of bacteria.  
 
10 uL of the S. equi cells resuspended in PBS was then added on each well of the 
10-well slide (EQ-299L). Briefly, since each slide has 10 wells, the first three 
wells were loaded with the strain 99 of S. equi, the second three wells were loaded 
with the strain 100, the third three were loaded with the vaccine strain and the last 
well was loaded with the strain 100 for the negative control group. 
 
After loading S. equi cells, slides were dried in 37 
o
C incubator followed by 10 
minutes incubation in an 80 
o
C incubator. Slides were then laid on a lab bench to 
cool. Subsequently, slides were immersed in 100% acetone for 10 minutes to fix 
the cells, dried in a fumehood and placed at - 20 
o
C for storage. 
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2.2.8 Serological Test by Indirect Fluorescent-antibody Assay 
 
Ten microliters of horse sera serially diluted with PBS-T/NaAz to a titre of 1/1000, 
1/500, and 1/100 were added to each well coated with bacteria. Generally, sera 
from infected or post-vaccinated horses were loaded on different slides. Since 
there were three S. equi strains fixed on each slide, for each strain serial sera 
dilutions (1/1000, 1/500 and 1/100) were added on each well, respectively. An 
exception to this procedure was the pre-vaccinated foal sera where an antibody 
titre of 1/500, 1/100 and 1/10 diluted sera were used for each S. equi strain. For 
the negative control group, 10 uL of PBS-T/NaAz was added instead of diluted 
sera. Slides were then incubated at 37 
o
C for 30 minutes. Subsequently, unbound 
sera were washed off from slides and slides were washed with PBS-T in a covered 
light-proof box while shaking for 15 minutes on an orbital shaker. Subsequently, 
slides were dried at 37 
o
C. Ten microliters of FITC conjugate was added on each 
well of the dried slides followed by another incubation step at 37 
o
C for 30 
minutes. Unbound conjugate was washed off from the slides and washed with 
PBS-T as described above. Slides were finally rinsed with tap water and dried at 
37 
o
C. 
 
2.2.9 Fluorescence Microscopy 
 
One drop of immersion oil was added on each well of the dried slides. S. equi 
cells were observed at 400 times magnification. The brightness of the 
fluorescently labelled bacteria observed with fluorescence microscopy was scored 
according to a four step scale (1, 2, 3 or 4), with 4 being the brightest. 
 
 
2.3 Enzyme-linked Immunosorbent Assay for Three     
SeM Peptides 
 
2.3.1 Synthesis of SeM Peptides 
 
Three biotinylated SeM peptides (Table 2.2) were synthesized from Genscript 
(Genscript, USA). These sequences were from the 5’ variable end of the SeM 
gene. 
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Table 2.2 Sequences of SeM peptides synthesized from Genscript 
Peptide Sequences 
SeM 99 SDIAIGRDASSAQKVRNLLK 
SeM 100 SDIAIGGDASSAPKVRNLLK 
SeM 2 SDIAISGDASSAQKVRNLLK 
 
2.3.2 Preparation of Streptavidin 
 
Streptavidin is the most popular and a widely available biotin-binding protein for 
ELISA studies. Streptavidin has an isoelectric point between 5 and 6, resulting in 
low nonspecific interactions. Ten microlitres of stock streptavidin was dissolved 
in 10 mL PBS to make a 5 ng/uL solution for coating plates. Fifty microlitres of 
this solution was used to coat 8 well ELISA strips (Costar, USA). 
 
2.3.3 Preparation of Blocking Buffer – Fetal Calf Serum (FCS) 
 
FCS is a commonly used blocking agent for blocking non-specific binding.  FCS 
was stored at -20 
o
C. To make 50 mL of 10% FCS blocking buffer, 5 mL of FCS 
was added to 45 mL of 0.3 M NaAc buffer pH 5.2.    
 
2.3.4 Preparation of 1:15000 Anti-horse IgG Horseradish 
Peroxidase (HRP) Conjugate (Sigma, U.S.A) 
 
HRP can oxidize chromogenic substrates (such as TMB) into coloured products 
using hydrogen peroxide (H2O2) as the oxidizing agent. This is detectable using 
spectrophotometric methods. To make 15 mL 1:15000 HRP conjugate, 1 uL of 
HRP stock solution and 0.45 g bovine serum albumin (BSA) (Sigma-Aldrich, 
USA) were dissolved in 15 mL PBS-T. 
 
2.3.5 Preparation of Substrate 
 
The substrate used in this study was 3, 3’, 5, 5’-Tetramethylbenzidine (TMB) 
(Sigma, U.S.A). It can produce a soluble product which is pale blue in colour 
when catalyzed by HRP and can be read spectrophotometrically at 370 or 620-650 
nm. The TMB reaction is stopped by adding 2 M H2SO4 resulting in a yellow 
colour, which is read at 450 nm. To make 10 mL of substrate, 0.1 mL of TMB and 
3 uL of cold H2O2 were added into 9.9 ml citrate phosphate buffer pH 5.5. 
 
2.3.6 ELISA for SeM Peptides 
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Ninety-six well microtiter strips (Costar, USA) were coated with 50 uL diluted 
streptavidin, giving a final concentration of 250 ng/well of streptavidin. Coated 
plates were placed on a flat surface at 4 
o
C overnight.  
 
On the second day, wells were washed three times with PBS-T using Wellwash 
Versa (Thermo Scientific, USA) and 100 uL of SeM peptides (strain 99 or strain 
100 or vaccine strain) at a concentration of 1 ng/uL was added into each well. 
After incubation of the plates at 37 
o
C for 1 hour, wells were washed two times in 
distilled water and then blocked with 200 uL of 10% FCS in NaAc buffer (pH 5.2). 
Plates were then incubated for another 1 hour at 37 
o
C and washed three times in 
distilled water. Subsequently, plates were dried in a fumehood and stored at - 20 
o
C. 
 
Blocked plates were washed three times with PBS-T and 50 uL of 1/10 diluted 
sera were added into each appropriate sample well. After incubation at 37 
o
C for 1 
hour, plates were washed six times in PBS-T. Fifty microliters of HRP conjugate 
was then added into each well and plates were incubated at 37 
o
C for 1 hour.  
Following that, plates were washed three times in PBS-T and two times in 
distilled water. Fifty microliters of TMB substrate was added into each well and 
plates were incubated at room temperature for 20 minutes. Finally, the reaction 
was stopped by adding 50 ul of 2M H2SO4 and the absorbance at 450 nm were 
measured using Multiskan Go (Thermo Scientific, USA). 
 
 
2.4  Enzyme-linked Immunosorbent Assay for PEPK     
Peptide 
 
2.4.1 Synthesis of PEPK Peptide 
 
PEPK peptide was synthesised commercially by GenScript (GenScript, USA). 
The synthesised peptide sequence is shown in table 2.3. The peptide was 
dissolved in water with DMSO according to guidelines from GenScript. The final 
concentration of the peptide was 1000 ug/mL. 
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Table 2.3 Sequence of PEPK peptide synthesized from Genscript 
Peptide name   Sequence 
PEPK PEPKPEPKPEPKPEPKPEPK 
 
 
2.4.2 ELISA for PEPK peptide 
 
The 96-well plate was coated with 50 uL of 10 ug/mL PEPK peptide and 
incubated overnight at 4 
o
C. On the second day, each well was washed once with 
distilled water. Then 100 uL of blocking buffer, 10% FCS in 0.3 M NaAc, was 
added to each well and the plate was incubated at 37 
o
C for one hour followed by 
three times washing with PBS-T. Subsequently, 50 uL of 1/10 diluted sera was 
added into each well. All samples were done in duplicate in order to increase the 
accuracy of this assay. After one hour incubation at 37 
o
C, wells were washed six 
times with PBS-T. 50 uL of HRP conjugate was then added into each well and 
plates were incubated at 37 
o
C for one hour. The plate was washed three times in 
PBS-T and three times in distilled water. Fifty microliters of TMB substrate was 
added into each well after the washing step and plates were incubated for 20 
minutes at room temperature. Finally, 50 uL of 2M H2SO4 was added to stop the 
reaction and the absorbance at 450 nm was measured. 
 
 
2.5  Complement Mediated Antibody Bactericidal Assay 
 
2.5.1 Preparation of PBS with Ca2+ and Mg2+  
 
To make 1 L of PBS with Ca
2+
 and Mg
2+
, 800 mL water was added into 100 mL 
10 X PBS. Subsequently 0.1 g CaCl2 and 0.1 g MgCl2 were dissolved into the 
above solution. The pH of the solution was adjusted to 7.4 and water was added to 
make a 1 L solution. The final concentration of Ca
2+
 was 0.9 mM and Mg
2+
 was 
0.49 mM. Finally the solution was sterilized by autoclaving and stored at room 
temperature. 
 
2.5.2 Preparation of Complement 
 
Lyophilized complement (sigma S1639, USA) was rehydrated with 5 mL of 
sterile water. This solution was then aliquoted in 0.1 mL volumes and stored at -
80
o
C until needed for use. 
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2.5.3 Preparation of S. equi for Bactericidal Assay 
 
Three S. equi strains (strains 99, 100 and vaccine strain) were tested for antibody 
complement mediated killing assay. The three S. equi strains were cultured on a 
blood agar plate at 37 
o
C overnight. On the second day morning, each strain was 
inoculated into a tissue culture flask with 10 mL BHI + 1% YE and was then 
incubated at 37 
o
C with shaking. Then 0.5 mL of mid log phage culture of each 
strain was harvested by centrifugation at 13,000 rpm for 15 minutes. Finally cells 
were washed by resuspending in 10 mL sterilized PBS with Mg
2+
 and Ca
2+
 (pH 
7.4). 
 
2.5.4 Sera Used for Bactericidal Assay 
 
Four sera were used for the bactericidal assay. One serum was from horse No. SI-
10, a stud S horse naturally infected with S. equi strain 100. Another serum was 
obtained from a horse (No. 36) recently vaccinated with Pinnacle strain. The other 
two samples were from stud A (No. 13 and 15). The horse No. 15 was infected 
with S. equi strain 99; whereas horse No. 13 was infected with strain 100. 
 
2.5.5 Complement Mediated Bactericidal Assay 
 
For each serum, four wells on a sterilized microtiter plate were used. First of all, 
25 uL of sterile PBS pH 7.4 was added into each well followed by 25 uL of 
complement inactivated serum loaded into each well. 25 uL of S. equi strains 99, 
100 and the vaccine strain in PBS pH7.4 was added into the first three wells, 
respectively. The last well was the control group. For the serum from horse No. 
15, 25 uL of strain 99 was added; for sera from horse No. SI-10 and No. 13, 25 uL 
of strain 100 was added into each well; for serum from horse No. 36, 25 uL of 
vaccine strain was added. This was done in a Biological Safety hood. The 
microtiter plate was incubated in 37 
0
C shaker incubator for 30 minutes 
(Multiskan Go, Thermo Scientific).  
  
Subsequently, plate was taken back to the biological safety hood. 25 uL of 
complement was added into each non-control group well. For the control groups, 
25 uL of PBS with Mg
2+
 and Ca
2+
 (pH 7.4) was added. After incubation in 37 
o
C 
shaker incubator for one hour, 50 uL of the solution in each well was spread on a 
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pre-warmed blood agar plate separately. Agar plates were then incubated in a 37 
o
C incubator overnight. On the next day, colonies were counted and percent 
killing was determined by the formula: % killing = [(CFUcontr. – CFUexp.)/CFUcontr.] 
X 100. 
  
   
 
2.6  Western Blotting 
 
2.6.1 Whole S. equi Cell Poteins Extraction 
 
S. equi strains 99, 100 and the vaccine strain were grown on blood agar plate 
overnight. On the afternoon of the second day each S. equi strain was inoculated 
into a cell tissue culture flask containing 10 mL BHI + 1% YE broth and was 
shaking at 37 
o
C in a orbital shaker overnight. On the next morning (day 3), each 
S. equi strain culture was transferred into a 15 mL falcon tube and centrifuged at 
4,500 g for 15 minutes. After centrifugation, the supernatant was tipped off and 
the cell pellet was resuspended in 1 mL of 100% cold acetone stored at -20 
o
C. 
Resuspended cells were then transferred into an eppendorf tube and rotated on a 
wheel for 10 minutes to ensure complete resuspension. Subsequently, cells were 
centrifuged in a table centrifuge at 13,000 rpm for 1 minute. After thoroughly 
tipping off the supernatant, cells were resuspended in 90 uL of TE and 10 uL of 
lysosome followed by incubation at 37 
o
C for 30 minutes with shaking at 600 rpm. 
After repeating the centrifugation step, the supernatant was tipped off and the 
remaining pellet was resuspended by 75 uL of water and 25 uL of 4 X loading 
buffer (Table 2.4).  
 
Table 2.4 Composition of 4 X loading buffer 
Chemicals in 4 X SDS 
loading buffer 
Concentrations Amount to make 10 mL 
Tris HCl pH 6.8 250 mM 2.5 mL 1 M Tris HCl pH 6.8 
Glycerol 20% v/v 2 mL 
SDS 4% v/v 4 mL 10% SDS 
Mercaptoethanol 10% v/v 1 mL 
Bromophenol blue 0.025% w/v 0.025 mL of 1% bromophenol blue 
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2.6.2 Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
 
Denaturing polyacrylamide gel electrophoresis was performed for the separation 
of whole cell proteins. The procedure consists of three stages: gel preparation, 
smaple preparation and electrophoresis. The glass plates and spacers were cleaned 
with tap water, dried with paper towels, and then cleaned again with 100% 
ethanol or acetone. Prepared plates were placed in a Hoefer gel caster. 12 % SDS-
PAGE gel was used to separate proteins of S. equi. Stacking gel and separating 
gels were prepared according to the appropriate composition shown in table 2.5 
and 2.6. Ammonium persulfate (APS) and TEMED (N, N, N´, N´-tetramethyl-
ethylenediamine) were added immediately just before gel casting.  The separating 
gel was prepared in a 15 mL falcon tube (Cellstar) and then immediately poured 
into the gel caster. Each gel was overlaid with 2mL of isopropanol and left at 
room temperature to set. This will take approximately 40 mins. All traces of 
isopropanol must be removed and then the stacking gel was poured followed by 
insertion of gel combs. Time to polymerise is approximately 30 mins. Gels for 
future use can be stored at 4 
o
C in damp paper towels and inside a sealed plastic 
bag, for ~1 month. 
 
Table 2.5 Composition of separating gels (12%) 
Reagent Volumes ⃰  in mL 
dd H2O 10.05 
30% acrylamide 12.00 
Resolving buffer (1.5M Tris pH 8.8) 7.50 
10% SDS w/v 0.30 
10% APS w/v 0.15 
TEMED 0.015 
total 30.015 
                  ⃰ Sufficient to prepare 5 small gels 
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Table 2.6 Composition of stacking gels 
Reagent Volumes ⃰  in mL 
ddH2O 8.5 
30% acrylamide 2.125 
Stacking buffer (1.0M Tris pH 6.8) 1.6 
10% SDS w/v  0.125 
10% APS w/v 0.063 
TEMED 0.0063 
Total ~12.5 
                  ⃰ Sufficient to prepare 5 small gels 
 
 
Fifteen microlitres of each sample were loaded into different wells and 4 uL of 
Precison Plus Protein Ladder (Bio-Rad Laboratories, USA) was added to an 
outside well. Gels were electrophoresed at 15 mA until the dye reached the 
separating gel and then at 30 mA until the dye reached the bottom of the gel.  
 
2.6.3 Protein Transfer 
 
Proteins were electrophorectically transferred with a nitrocellulose membrane, 
using a fully submerged blotting apparatus (Biorad Mini-Trans-Blot, USA). The 
arrangement of the blot is illustrated in Figure 2.1. The introcellulose and four 
pieces of 3MM filter paper were cut slightly bigger than the gel to ensure effective 
protein transfer. The sandwich was assembled as in Figure 2.1 and transferred to 
the blotting tank, along with an ice container and stirrer magnet. Transfer buffer 
(25 mM Tris, 192 mM glycine, 20% methanol, 0.01% SDS) was added to 
fullsubmerge the sandwich. The transfer was run at 50 V for 2 hours.   
 
 
 
             Figure 2.1 Arrangements of components used in western blotting  
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2.6.4 Antibody Binding 
 
After the proteins were transferred to the membrane the blotting apparatus was 
carefully disassembled. Membrane was stained by ponceau (0.2% ponceau, 1% 
acetic acid) for 5 minutes to check the transfer efficiency. The membrane was 
rinsed with distilled water and transferred to a new container with 50 mL of 
BLOTTO (10% skim milk in PBS-T) to block the non-specific binding and left at 
4 
o
C overnight. Then the membrane was transferred onto a glass plate and 
appropriately diluted horse serum in BLOTTO was added on the top of the 
membrane followed by incubation for one hour at room temperature. Serum from 
pre-vaccinated horse was diluted 100 times in BLOTTO and sera from post-
vaccinated or infected horses were diluted 1000 times in BLOTTO.  
 
After incubation, the membrane was washed with PBS-T three times for 15 
minutes. The membrane was then put back to a new glass plate and incubated 
with secondary antibody (anti-horse IgG HRP conjugate diluted 5000 times in 
BLOTTO) for one hour followed by another washing step as before.  
 
2.6.5 Immunodetection 
 
The secondary antibody was detected using SuperSignal
®
 West Femto Maximum 
Sensitivity Substrate (Thermo Scinetific, USA). Immunodetection was carried out 
according to the manufacturer’s directions. Generally, the membrane was 
transferred to a glass plate with protein-side up. 2 mL Substrate solution (500 uL 
of detection solution 1, 500 uL of detection solution 2 and 1 mL ddH2O) was 
added on the membrane and the membrane was incubated with substrate for 30 
seconds at room temperature. Excess substrate was removed by placing an OHT 
sheet over the membrane. The membrane was then expsoed for 20 seconds using a 
FUJIFILM Intelligent dark box II LAS-1000 system.   
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Chapter Three 
 
Results  
 
 
3.1 Sample Size 
 
Sera were obtained from 139 horses and used for this study. Horses were either 
naturally infected by S. equi, or vaccinated with Pinnacle or Equivac S. Detailed 
information about horses is in appendix A. 
 
Sera were used for indirect fluorescence antibody assay (IFA), enzyme linked 
immunosorbent assay (ELISA), Western blotting and complement mediated 
bactericidal assay.  
 
Three strains of S. equi were used as antigens in the serological evaluation. These 
were strain 99, strain 100 and the Pinnacle vaccine strain (strain 2). 
 
 
3.2 Western Blotting Results 
 
Five sera were used for western blotting study. The two sera from stud O were 
taken from pre- and post-vaccinated horse No. 36, which used the Pinnacle 
vaccine. One serum was from post-vaccinated horse J of stud W, vaccinated with 
Equivac S, and the other two sera were from infected horses (SI-10 and No. 15) of 
stud S and stud A, respectively. The titre of the serum for the pre-vaccinated horse 
was 1/100 for western blotting. Whereas all the other sera were used at titre of 
1/1000. Sodium dodecyl sulphate extracted proteins from three S. equi strains 
(strain 99, strain 100 and the vaccine strain) were used as target antigens. 
 
3.2.1 SDS-PAGE Gel Result  
 
The SDS-PAGE gel (Fig. 3.1) showed that the proteins profiles extracted from 
these three S. equi strains were similar. They all had proteins that ranged from 100 
kDa to 15 kDa in size. Protein around 27 kDa was produced at the highest level 
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compared to other proteins of S. equi. Also, three other proteins with sizes 
approximate 17 kDa, 49 kDa and 51 kDa expressed at higher quantities than the 
other proteins. 
 
 
 
Figure 3.1 SDS-PAGE gel results of proteins extracted from S. equi strain 99, 100 and 
vaccine strain. Lane 1, protein ladder; lane 2 to 4, 5 uL of protein samples from S. equi strain 
99, 100 and vaccine strain, respectively; lane 5 to 7, 10 uL of protein samples from S. equi 
strain 99, 100 and vaccine strain, respectively; lane 8 and 9, 15 uL of protein samples from S. 
equi strain 99 and 100 separately.  
 
3.2.2 Control Experiment of Western Blotting 
 
From the control experiment, it is clear that anti-horse IgG HRP conjugate can 
cross-react with some proteins from S. equi. These cross-reactions among proteins 
from three tested S. equi strains were the same (Fig. 3.2). HRP conjugate can 
cross-react with 5 proteins from S. equi. It had relative strong reactions with 
proteins around 26 kDa, 27 kDa, 37 kDa, 49 kDa. Its binding with protein around 
62 kDa was not obvious. 
 
 
 
 
 
 
 
 
 
1        2        3        4         5        6        7        8        9  
100 kDa 
75 kDa 
50 kDa 
25 kDa 
20 kDa 
51 kDa 
49 kDa 
27 kDa 
17 kDa 
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Figure 3.2 Control experiment of western blotting. Lane 1, protein sample from S. equi 
vaccine strain; lane 2, protein sample from strain 100; lane 3, protein sample from strain 99. 
 
3.2.3 Western Blotting Result of 1/100 Diluted Serum from A Pre-
vaccinated Horse 
 
Serum from pre-vaccinated horse 36 could bind several proteins from all three S. 
equi strains (Fig. 3.3). The antibodies interactions with proteins from strain 99 and 
strain 100 were similar. Mainly, these antibodies can bind to 8 proteins, sized 
around 26 kDa, 27kDa, 34 kDa, 35 kDa, 37 kDa, 49 kDa, 51 kDa and 62 kDa; 
Whilst, one more band (size 55 kDa) were seen on the membrane against proteins 
from vaccines strains compared with strains 99 and 100. The band at around 37 
kDa showed a strong fluorescent color, which means the strong interaction 
between the antibody in the serum and the protein from the S. equi vaccine strain. 
Moreover, the additional band seen at around 55 kDa against proteins from 
vaccine strain indicates a relative low amount of antibody existed in the serum 
that could bind this protein. The fluorescence of bands at size around 49 kDa and 
62 kDa was weaker for vaccine strain compared with the other two strains. 
 
 
 
 
 
 
 
 
      1          2       3  
62 kDa 
49 kDa 
37 kDa 
27 kDa 
26 kDa 
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Figure 3.3 Western blotting results when using 1/100 diluted serum from pre-vaccinated 
horse. Lane 1, protein sample from S. equi vaccine strain; lane 2, protein sample from strain 
100; lane 3, protein sample from strain 99. 
 
 
3.2.4 Western Blotting Result of 1/1000 Diluted Serum from A                    
Horse Vaccinated with Pinnacle 
 
More antibodies were induced within the horse serum (horse No. 36) after 
vaccination with Pinnacle (Fig. 3.4). The banding patterns for strain 99 and 100 
were similar. Moreover, compared with the patterns of banding when using pre-
vaccinated horse serum, there was no difference of the western blotting results for 
strains 99 and 100. There were still the same 8 bands on the membrane for strains 
99 and 100. However, one more band (size 31 kDa) seen on the membrane for 
vaccine strain compared with the result when using pre-vaccinated serum. 
 
 
 
 
 
 
 
 
 
 
  1           2           3    
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Figure 3.4 Western blotting Result of 1/1000 diluted Serum from Horse Vaccinated with 
Pinnacle. Lane 1, protein sample from S. equi vaccine strain; lane 2, protein sample from 
strain 100; lane 3, protein sample from strain 99. 
 
 
3.2.5 Western Blotting Result of 1/1000 Diluted Serum from A 
Horse Vaccinated with Equivac S 
 
After the horse (No. J) vaccinated with Equivac S, western blotting showed fewer 
bands on the membrane compared to the results which serum from horse 
vaccinated with Pinnacle (Fig. 3.5). The banding patterns for strain 99 and 100 
were similar but different from the vaccine strain. There were five bands (size 26 
kDa, 27 kDa, 49 kDa, 51 kDa and 62 kDa) shown on the membrane against 
proteins from strain 99/100. Also, there were five bands seen on the membrane 
against proteins from the vaccine strain, sized at around 26 kDa, 27 kDa, 51 kDa, 
55 kDa and 62 kDa.   
 
 
 
 
 
 
 
   1            2           3 
62 kDa 
55 kDa 
51 kDa 
49 kDa 
37 kDa 
35 kDa 
34 kDa 
31 kDa 
27 kDa 
26 kDa 
 32 
 
 
 
Figure 3.5 Western blotting results of 1/1000 diluted serum from horse vaccinated with 
Equivac S. Lane 1, protein sample from S. equi strain 100; lane 2, protein sample from strain 
99; lane 3, protein sample from vaccine strain. 
 
 
3.2.6 Western Blotting Result of 1/1000 Diluted Serum from 
Infected Horses 
  
When using sera from infected horses for western blotting, significantly more 
bands and stronger interactions can be seen on the membrane compared with the 
result when using serum from vaccinated horse (Fig. 3.6 and 3.7). The western 
blotting results were similar when using sera from these two infected horses. At 
least 16 bands were shown on the membrane. There sizes were ranged from 75 
kDa to 10 kDa. The banding patterns for strain 99 and 100 were similar compared 
with the vaccine strain. At least two more bands (size 18 kDa and 65 kDa) on the 
membrane against strain 99/100 compared with the vaccine strain. Moreover, 
stronger interactions between serum and protein (size 25 kDa) of strain 99/100 
compared with the vaccine strain. 
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Figure 3.6 Western Blotting Result of 1/1000 Diluted Serum from Infected Horse (No. 15). 
Lane 1, protein sample from S. equi vaccine strain; lane 2, protein sample from strain 100; 
lane 3, protein sample from strain 99.  
 
 
 
 
Figure 3.7 Western Blotting Result of 1/1000 Diluted Serum from Infected Horse (No. SI-10). 
Lane 1, protein sample from S. equi vaccine strain; lane 2, protein sample from strain 100; 
lane 3, protein sample from strain 99.   
 
 
 
3.3 Indirect Fluorescent-antibody Assay (IFA) results 
 
IFA was used to demonstrate the presence of antibodies in horse serum against the 
three different strains of S. equi. Acetone fixed S. equi bacterial cells were 
incubated with the horse’s serum. Excess serum was washed away, leaving only 
      1          2          3   
      1         2          3   
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 34 
 
antibodies specific for S. equi. The sample was then incubated with Anti-Horse 
IgG-FITC antibody (Sigma, USA) and viewed with a fluorescent microscope. 
 
Four arbitrary scores were used to determine the intensity of fluorescence due to 
antibodies present in the horse serum against S. equi. An IFA result with score I 
indicates the least fluorescently active; whereas an IFA result with score IV 
indicates the most fluorescently active. I have chosen a score of two as the cut-off. 
 
 
 
 
Figure 3.8 Different scores of IFA results. a.) score 1. b.) score 2. c.) score 3. d.) score 4. e.) 
score 0 (negative control).  
 
 
3.3.1 IFA Results of Sera from Stud O 
 
Five pre-vaccinated weanling and nine post-vaccinated (using Pinnacle vaccine) 
horses were studied. The pre-vaccinated horses were screened at lower titers (1/10 
a
. 
b
. 
c
. 
d
. 
e
. 
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to 1/500), as it was assumed that this group of horses would be immunologically 
naive to S. equi antigens.  
 
All the sera from pre-vaccinated horses recorded titre of 1/100 against all three 
strains of S. equi, with possible slightly higher reactivity to the vaccine strain 
(Table 3.1). There was some slight reactivity to all three strains at titre of 1/500, 
like sera from 37 against S. equi vaccine strain. 
 
Table 3.1 IFA result of pre-vaccinated sera from stud O 
 
 
 
For the post-vaccinated horses, the sera were screened at titres from 1/100 to 
1/1000. Samples 36 to 40 were the duplicates of the pre-vaccinated horses. 
Vaccination consisted of 2 shots of Pinnacle vaccine 20 days apart and bloods 
were taken 8 days later. All of the sera showed increased antibodies at titre of 
1/1000 to the Pinnacle vaccine strain, whilst the majority of samples also had 
antibodies at 1/1000 titre to strains 99 and 100 (Table 3.2). There were three 
exceptions. 
 
Post-vaccinated horses 41 to 44 received their annual booster with Pinnacle and 
were sampled 12 days later. These samples generally showed greater serological 
reactivity to strains 99 and 100 as compared with the vaccine strain. 
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Table 3.2 resutls of post-vaccinated sera from stud O 
 
 
 
3.3.2 IFA Results of Sera from Stud W 
 
Horses at stud W had a regular vaccination schedule with Equivac S. Sera samples 
were obtained from 27 horses (No. A to AA) which were just before (T0) and 30 
days after (T30) vaccination this season. All the sera were screened at titres from 
1/100 to 1/1000. It is clear that all of the sera had good titres with all three S. equi 
strains examined at different titer points (Table 3.3). The induced antibody levels 
against three S. equi strains were variable among horses. For horses L, M and P, 
their sera have relative high immunological responses (scored around 3 with 
1/1000 diluted sera) against the three S. equi strains, regardless of being or not 
being vaccinated this season; whereas, the sera from horses X and B have slightly 
lower levels of antibody against all three S. equi strains compared with other sera. 
 
For most horses, there was no obvious increase of antibody levels after 
vaccination this season from IFA results. However, after vaccination this season, 
the serum of horse N had a slight increase in immunofluorescence against strain 
99. The serum of horse U had higher immunological reactivity against strain 100. 
The sera of horses J and R had increased antibody responses against strain 99 and 
the vaccine strain. The sera of horses C, E and I had more antibodies against 
vaccine strain. Moreover, the sera of horses G, H and Y had increased antibody 
responses against all S. equi strains tested.  
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Samples from horse B showed lower serological reactivity to strain 99 compared 
with strain 100 and the vaccine strain at titer of 1/1000. Samples from horse F 
showed higher antibody responses to the vaccine strain compared with strains 99 
and 100. After vaccination this season, serum from horse I showed decreased 
immunological reactivity to strain 99 and 100 but increased serological reactivity 
to the vaccine strain. Before vaccination this season, serum from horse J had 
higher immunological responses to strain 100 compared with strain 99 and the 
vaccine strain at all titres. 
 
Before vaccination this season, serum from Screen Idol showed higher antibodies 
levels of strain 99 and strain 100 compared with vaccine strain at titres of 1/1000 
and 1/500. However, after vaccination its sera showed decreased antibodies 
response to strain 99 at titres of 1/1000 and 1/500, but a slight increase of 
serological reactivity to vaccine strain at titre of 1/1000. 
 
Serum from horse S had decreased antibody responses to all three strains after 
vaccination. Sera from horse AA had slightly more serological activity to strain 
99 and 100 compared with vaccine strain.  
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Table 3.3 IFA results of sera from stud W 
Horse No. status Strain 99 Strain 100 Vaccine strain 
  1/1000 1/500 1/100 1/1000 1/500 1/100 1/1000 1/500 1/100 
A  T0 2 3 4 2 2+ 3+ 2 2 4 
T30  2 3 4 2 3 3+ 2 2+ 4 
B 
 
T0 1 2 4 2 2 3 2 2 4 
T30 1 2 4 2 2 3+ 1 2 4 
C T0 2 3 4 2 3 3+ 2 2 4 
T30 2 3 4 2+ 3 4 2+ 3+ 4 
D T0 2 2 3+ 2 2 3 2 2 4 
T30 2 2 3 2 3 3 2 3 4 
E T0 2 3 4 2 2+ 3 2 2 4 
T30 2 3 4 2 2+ 3+ 3 3 4 
F T0 2 2 4 2 2 3+ 2+ 3 4 
T30 2 2 4 2 2+ 4 2 3 4 
G T0 2 3 4 2 3 4 2+ 3 4 
T30 3 3 4 3 3 4 3 4 4 
H T0 2 3 4 2 3 4 2 2 3+ 
T30 3 3 4 3 3+ 4 2 3 4 
I T0 2 3 4 2 3+ 4 2 3+ 4 
T30 1 2 4 2 2+ 4 3 3+ 4 
J  T0 2 2+ 3 3 4 4 2 2 3 
T30 3 4 4 3 4 4 4 4 4 
K  T0 3+ 4 4 3 4 4 2 3 4 
T30 2 2+ 4 3 3+ 4 3 3 4 
L  T0 3 4 4 3 3+ 4 3 3+ 4 
T30 3 3+ 4 3 3+ 4 3 4 4 
M T0 3 3+ 4 3 3+ 4 3 3 4 
T30 3+ 4 4 3 3+ 4 3 3+ 4 
N  T0 2 2+ 4 3 3+ 4 2 3 4 
T30 2+ 3+ 4 2 3 4 2 3 4 
O T0 2 3 4 2 3 4 2 3+ 4 
T30 2 2+ 4 2 2+ 4 3 3+ 4 
P T0 3 4 4 3 3+ 4 2+ 3 4 
T30 3 4 4 3 4 4 3 4 4 
Q T0 2 3 4 3 4 4 3 3+ 4 
T30 3 3+ 4 2+ 3+ 4 3 3 4 
R T0 2 3+ 4 2 4 4 1 2+ 4 
T30 3 4 4 2 3+ 4 3 3 4 
S T0 3 4 4 3 4 4 3 3 4 
T30 2 3 4 3 3 4 2 2 4 
T T0 3 3 4 3 3+ 4 2 2+ 3+ 
T30 2 3 4 2+ 3 4 2 3 4 
U  T0 2 2+ 4 2 2+ 4 2 2+ 4 
T30 2 2+ 4 3 4 4 2 3 4 
V T0 2 3+ 4 2 3 4 2 2+ 4 
T30 2 2+ 4 1+ 2+ 4 2 3 4 
W T0 3  3+ 4 2+ 3+ 4 2 3+ 4 
T30 2 3 3+ 2 3+ 4 1 2 3+ 
X T0 1 2+ 4 1 3 4 1 2 4 
T30 1 2+ 4 2 2+ 4 1 2+ 4 
Y T0 2 3 4 2 3 4 1 3 4 
T30 3 4 4 3 4 4 2 3 4 
Z T0 2 3 4 2 3 4 2 3 4 
T30 2 3 4 2 3 4 2 2+ 4 
AA T0 2 2+ 4 2 3 4 1 2 3 
T30 2 2+ 4 2 3 4 1 2 4 
T0: the day for booster; T30: 30 days after booster. 
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3.3.3 IFA Results of Sera from Stud A 
 
Forty three sera samples were received from stud A, which experienced an 
outbreak of strangles at the time the sera were collected. All the sera were 
screened at titres from 1/100 to 1/1000. IFA results showed that all sera titers had 
antibody responses against these three S. equi strains tested (Table 3.4).  
 
Twenty two sera samples were taken from 11 horses before vaccination on day 0 
and post-vaccination this season. Two horses – 22 and 28, their antibodies levels 
within their sera did not have any increase after vaccination. A slight increase of 
antibody responses to all examined S. equi strains was seen after vaccination of 
four horses.   
 
Increased serological reactivity of serum from horse 34 to the vaccine strain was 
seen after vaccination. However, serum from horse 33 showed decreased antibody 
responses to the vaccine strain after vaccination. 
 
Serum from horse 32 showed a slight increase of immunological reactivity against 
strain 99 after vaccination, but having decreased serological reactivity to strain 
100 and the vaccine strain.  
 
Serum from horse 35 had decreased serological reactivity against strain 99 and 
100 after vaccination.   
 
Horses 1, 2, 3, 4, 5, 8, 10, 11, 12, 13, 14, 15, 17, 23, 25 and 29, their sera showed 
higher serological reactivity to the vaccine strain compared with strain 99 and 100.   
 
For those infected horses (No. 5, 6, 13 and 15), most of their sera had relatively 
higher serological responses to the vaccine strain compared with strain 99 and 100. 
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Table 3.4 IFA results of sera from stud A 
Horse 
No. 
status Strain 99 Strain 100 Vaccine strain 
  1/1000 1/500 1/100 1/1000 1/500 1/100 1/1000 1/500 1/100 
1  2 4 4 3 3 4 4 4 4 
2  2 3 4 3 3 3 3 4 4 
3  1 2 3 2 2 4 4 4 4 
4  2 2 3 1 2 3 4 4 4 
5 Infected 2 3 4 2 3 4 3 4 4 
6 Infected 2 3 4 2 3 4 2 3 4+ 
7  1 2 3 2 2 3 2+ 3 4 
8  1 2 3 1 1 2 2 2+ 3 
9  2 3 4 3 3 3 2 3 4 
10  1 3 4 2 3 3 3 3 4 
11  1 2 4 2 2 3 3 3 4 
12  2 3 4 2 2 3 3+ 4 4 
13 Infected 2 2 4 0 0 3 3 4 4 
14  2 3 4 2+ 3+ 0 3 3+ 4+ 
15 infected 2 3 4 2 2+ 4 3 3 4 
16  2 3 4 2 2 2+ 2 2 4 
17  1 2 4 1 2 3 3 4 4 
18  2 3 4 2 3 3 2 2 4 
19  2 3 4 2 2 3 2 3 4 
20 b/f  ⃰  1 1 3 2 2 3+ 1 2 4 
     a/f † 2 2+ 3+ 2 3 4 2 3 4 
21 b/f 2 2 3+ 2 3 4 2 3 4 
22 b/f 2 2+ 4 2 3 4 3 3 4 
a/f 2 3 4 2+ 3 4 2+ 3 4 
23 b/f 1 2 3+ 1 2 4 2 2 4 
24 b/f 2 2 4 2 2+ 4 2 2 3 
25 b/f 2 3 4 1 2 4 3 3 4 
26 b/f 2 3 4 1 2 4 2 2 4 
a/f 2+ 2+ 4 2 2+ 3+ 2+ 3 4 
27 b/f 1 2 4 1 2 4 1 2 4 
a/f 2 2+ 3+ 2 2+ 4 2 3 4 
28 b/f 2 3 4 2 3 4 3 3 4 
a/f 2 2+ 4 2+ 3 4 2 3 4 
29 b/f 1 2 4 1 2+ 4 2 3 4 
30 b/f 1 2 3 1 2 4 2 3 4 
a/f 2 2+ 3+ 2 3 3+ 2 3 4 
31 b/f 2 2 3 1 2 3+ 1 2 3 
a/f 2 2+ 3+ 2 2+ 3+ 2 2 3 
32 b/f 1 2 3+ 2 2+ 4 2 3 4 
a/f 2 2 3+ 1 2 3+ 1 2 4 
33 
 
b/f 2 2+ 4 2 2+ 3+ 3 3+ 4 
a/f 2 2+ 4 2 2+ 3+ 2 3 4 
34 b/f 1 2 3 2 3 3+ 1 1 3 
a/f 2 2 3+ 2 2+ 3+ 2 3 4 
35 
 
b/f 2 2+ 4 2 2+ 4 2 3 4 
a/f 1 2 3+ 1 2 3+ 2 3 4 
36 a/f 2+ 3 4 2+ 3 3+ 2 3 4 
⃰ b/f: before booster this season. † a/f: after booster this season. 
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3.3.4 IFA Results of Sera from Stud S 
 
Sera from 18 horses (No. SI-1 to SI-18) were tested for IFA. All the sera were 
screened at titres from 1/100 to 1/1000. IFA results showed that all sera titers had 
antibodies against S. equi (Table 3.5). 
 
Horse SI-11 was vaccinated with Pinnacle last season. Its sera were received 
before and after vaccination with Equivac 2in1 this season. The IFA results 
showed the antibodies levels against S. equi of pre- and post-vaccinated sera were 
similar. Sera taken pre- and post-vaccination both showed higher antibody 
responses to strain 99 at titre of 1/500, compared with strain 100 and the vaccine 
strain.  
 
Horse SI-18 was vaccinated with Equivac 2in1 on 16-11-2010 and its serum was 
received on 15-10-2012. An intense bright green colour was visualized when 
1/1000 diluted sera reacted with those three S. equi strains, and the intensity of 
these reactions were all scored between two and three. Its serum showed relatively 
lower serological reactivity to the vaccine strain compared with strains 99 and 100.  
 
The mare SI-17 had previously been vaccinated with Pinnacle (2011/2012 season) 
and boosted with Equivac 2in1 on 10-10-12. Two blood samples were received 
five days after booster this season. Antibodies were induced at relative high levels 
against all three S. equi strains. 
 
Serum from infected horse (SI-10) had similar antibodies levels compared to other 
vaccinated horses from stud S.  
 
The sera of the other horses from Stud S were all taken before vaccination with 
Equivac 2in1 this season. Sera from five horses showed lower serological activity 
to vaccine strain compared with strain 99 and strain 100; whereas, sera from horse 
SI-12 showed lower serological reactivity to strain 99 and 100. Moreover, Sera 
from horses SI-7, SI-9, and SI-14 had lower antibodies response to strain 100 and 
the vaccine strain. 
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Table 3.5 IFA results of sera from stud S 
Horse 
No. 
status Strain 99 Strain 100 Vaccine strain 
  1/1000 1/500 1/100 1/1000 1/500 1/100 1/100
0 
1/50
0 
1/100 
SI-1  2+ 3 4 2 3 4 1 2 3 
SI-2  2 3 4 2+ 3 4 1 2 4 
SI-3  2 3 4 2+ 3+ 4 1 2 4 
SI-4  3 3 4 2 3 4 2 2 4 
SI-5  3 3+ 4 2+ 3+ 4 2 3 4 
SI-6  2 2+ 3+ 2 2 3+ 2 3 4 
SI-7  2 2+ 4 1 2 4 1 2 4 
SI-8  2+ 3 4 2 2 4 2 2 3+ 
SI-9  3 4 4 1 2 3+ 1 2 4 
SI-10 Infected  2 2+ 4 2 3 4 2 3 4 
SI-11 B/F  ⃰ 1 3 4 1+ 2+ 4 2 2 4 
A/F † 2 2+ 4 2 2 4 1 2 4 
SI-12  1 1 3 1 2 3 2 3 4 
SI-13  2 3 4 2 2 4 2 2 4 
SI-14  3 3 4 2 2 3+ 2 2 3 
SI-15  1 2 4 1 2 4 1 2 3 
SI-16  1 2 4 1 2 4 1 2 4 
SI-17  2 4 4 2 3 4 2 3 4 
SI-18  3 4 4 2 3+ 4 2 3 4 
SI-19 Post-vac 2+ 3+ 4 3 4 4 2 2 4 
SI-10 was infected with strain 100. SI-19 was vaccinated with Equivac 2in1 on 16/11/2010. B/F ⃰ : before 
booster this season. A/F †: after booster this season.  
 
 
 
 
 
 
 
 43 
 
3.4  Results Enzyme-linked Immuno-sorbent Assay 
(ELISA)  
 
3.4.1 ELISA Results for Sera Against the Three Strain-specific 
SeM Peptides 
 
3.4.1.1 ELISA results for sera from stud O 
 
1/10 diluted sera from stud O were used for ELISA study. It is clear that all of the 
sera from Stud O showed serological reactivity to all three SeM peptides (Table 
3.6). The OD values of control was less than 0.05.  
 
After vaccination, only the OD values of sera from horse 36 increased against all 
three SeM peptides. The ODs of sera from horses 37 to 40 did not have much 
difference after vaccination. 
 
Table 3.6 ELISA results for sera from stud O 
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3.4.1.2 ELISA Results for Sera from Stud W 
 
1/10 diluted sera from stud W were used for ELISA study. It is clear that all of the 
sera from Stud W showed serological reactivity to all three SeM peptides and the 
serum antibody responses of individual horses to the SeM peptides were relative 
variable (Tables 3.7, 3.8 and 3.9). The ODs of control was lower than 0.05. 
 
Generally, after vaccination this season, the OD values of most sera to all three 
SeM peptides did not show much difference with the OD values before 
vaccination. 
 
 Some sera had increased antibody responses to SeM peptides after vaccination. 
Sera from T and X had slightly increased serological reactivity to SeM 99 peptide. 
Sera from D, E, H, K, M, O, R and Z showed slight increase of serological 
reactivity to SeM 100 peptide. Whereas, the ODs of sera from I and N against 
SeM vac peptide was higher after vaccination. Sera from P and Y had increased 
ODs to both SeM 99 and SeM 100 peptides, whilst sera from S showed increased 
ODs to SeM 99 and SeM vac peptides. 
 
On the other hand, some sera showed decreased antibody responses to SeM 
peptides after vaccination. Sera from A and N had slightly decreased serological 
reactivity to SeM 99 peptide. Sera from S showed slightly decreased 
immunological response to SeM 100 peptide. Whereas, the ODs of sera from D, H, 
O, T, V, W and X against SeM vac peptide was lower after vaccination.  
 
Sera from K and Q showed decreased ODs to all three peptides. Sera from F, G 
and U showed decreased ODs to SeM 100 and SeM vac peptides. Whereas, sera 
from B and C showed decreased ODs to SeM 99 and SeM vac peptides. 
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Table 3.7 ELISA Results for Sera from Stud W against SeM 99 peptide 
 
 In the horse No., 0 means serum was taken just before booster this season; 30 means serum was taken 30 
days after booster this season. 
 
Table 3.8 ELISA Results for Sera from Stud W against SeM 100 peptide 
 
In the horse No., 0 means serum was taken just before booster this season; 30 means serum was taken 30 days 
after booster this season. 
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Table 3.9 ELISA Results for Sera from Stud W against SeM vac peptide 
 
In the horse No., 0 means serum was taken just before booster this season; 30 means serum was taken 30 days 
after booster this season. 
 
 
3.4.1.3 ELISA Results for Sera from Stud A 
 
1/10 diluted sera from stud A were used for ELISA study. It is clear that all of the 
sera from Stud A showed serological reactivity to all three SeM peptides and the 
serum antibody responses of individual horses to the SeM peptides were relative 
variable. 
 
After vaccination, the sera from horse 20 showed slightly increased ODs to all 
three SeM peptides. The OD values of sera from horses 28 and 31 had a mild 
increase to SeM 99 and SeM vac peptides. Sera from horse 34 showed higher 
ODs to SeM 100 and SeM vac. Sera from horse 22 showed higher ODs to SeM 
100. Whereas, sera from horse 27 showed higher ODs to SeM vac. 
 
For those four infected horses, the ODs of their sera to all three SeM peptides did 
not show much difference with the ODs of other sera. 
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Table 3.10 ELISA Results for Sera from Stud A against SeM 99 peptide 
Horse No.  status OD-1 OD-2 Horse No. status OD-1 OD-2 
1 
 
0.484 0.2354 23 
 
0.2927 0.2974 
2 
 
0.496 0.2905 24 
 
0.2698 0.3001 
3 
 
1.027 0.4700 25 
 
0.2766 0.3539 
4 
 
0.358 0.2394 26 pre-vac 0.2582 0.2967 
5 infected  0.316 0.2472 26 post-vac 0.2433 0.3350 
6 infected  0.51 0.2801 27 pre-vac 0.2438 0.4037 
7 
 
0.3134 0.3643 27 post-vac 0.3119 0.3494 
8 
 0.2550 0.3275 
28 pre-vac 0.2512 0.3399 
9 
 
0.3024 0.3859 28 post-vac 0.3168 0.3401 
10 
 
0.2623 0.4042 29 
 
0.2610 0.3412 
11 
 
0.2704 0.3278 30 pre-vac 0.2447 0.3138 
12 
 
0.3099 0.2620 30 post-vac 0.3018 0.2817 
13 infected  0.3214 0.3388 31 pre-vac 0.2585 0.2745 
14 
 
0.3020 0.2646 31 post-vac 0.2811 0.4054 
15 infected  0.3214 0.2906 32 pre-vac 0.2711 0.3015 
16 
 
0.2953 0.2901 32 post-vac 0.2901 0.3120 
17 
 0.3171 0.3245 
33 pre-vac 0.2655 0.3580 
18 
 
0.2767 0.2777 33 post-vac 0.2919 0.3504 
19 
 
0.2588 0.3604 34 pre-vac 0.2679 0.3908 
20 pre-vac 0.2247 0.2975 34 post-vac 0.3025 0.3899 
20 post-vac 0.3618 0.3610 35 pre-vac 0.2814 0.3144 
21 
 
0.2590 0.3050 35 post-vac 0.3111 0.2779 
22 pre-vac 0.2794 0.2569 36 
 
0.2802 0.3713 
22 post-vac 0.2690 0.3170 NC 
 
0.046 0.045 
Pre-vac: before booster this season; post-vac: after booster this season; NC: control assay 
 
Table 3.11 ELISA Results for Sera from Stud A against SeM 100 peptide 
horse No.  status OD-1 OD-2 Horse No. status OD-1 OD-2 
1 
 
0.43 0.2412 23 
 
0.2979 0.2858 
2 
 
0.347 0.2169 24  0.2987 0.2918 
3 
 
0.799 0.3238 25 
 
0.3203 0.2308 
4 
 
0.347 0.2382 26 pre-vac 0.2979 0.2771 
5 infected  0.305 0.2120 26 post-vac 0.2909 0.2740 
6 infected  0.49 0.2174 27 pre-vac 0.2937 0.3450 
7 
 
0.3373 0.3879 27 post-vac 0.3121 0.2858 
8 
 0.2575 0.2548 
28 pre-vac 0.3174 0.3403 
9 
 
0.3423 0.3067 28 post-vac 0.3285 0.3945 
10 
 
0.2969 0.3042 29 
 
0.3209 0.3143 
11 
 0.2956 0.3157 
30 pre-vac 0.2936 0.2956 
12 
 
0.3080 0.2916 30 post-vac 0.2881 0.2248 
13 infected  0.3235 0.3584 31 pre-vac 0.3424 0.3098 
14 
 
0.3060 0.2970 31 post-vac 0.3079 0.2964 
15 infected  0.3385 0.3071 32 pre-vac 0.3106 0.2528 
16 
 
0.3139 0.3309 32 post-vac 0.2953 0.2598 
17 
 0.3206 0.2146 
33 pre-vac 0.3044 0.2782 
18 
 
0.2861 0.1359 33 post-vac 0.2948 0.2877 
19 
 0.2562 0.2692 
34 pre-vac 0.3281 0.2368 
20 pre-vac 0.2623 0.2347 34 post-vac 0.3457 0.4003 
20 post-vac 0.3176 0.2918 35 pre-vac 0.2854 0.2578 
21 
 0.2828 0.2305 
35 post-vac 0.2960 0.2546 
22 pre-vac 0.2872 0.2703 36 
 
0.2997 0.2661 
22 post-vac 0.2930 0.2805 NC  
0.042 0.048 
Pre-vac: before booster this season; post-vac: after booster this season; NC: control assay 
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Table 3.12 ELISA Results for Sera from Stud A against SeM vac peptide 
horse No.  status OD-1 OD-2 Horse No. status OD-1 OD-2 
1 
 
0.465 0.2946 23 
 
0.3161 0.2818 
2 
 
0.315 0.2341 24  0.2941 0.2981 
3 
 
0.752 0.4331 25 
 
0.2788 0.3571 
4 
 
0.337 0.2959 26 pre-vac 0.2522 0.2892 
5 infected  0.299 0.2282 26 post-vac 0.3006 0.2556 
6 infected  0.509 0.2658 27 pre-vac 0.2911 0.2954 
7 
 
0.3345 0.3430 27 post-vac 0.3553 0.3212 
8 
 
0.2769 0.2980 28 pre-vac 0.2915 0.3090 
9 
 
0.2996 0.3866 28 post-vac 0.3292 0.2639 
10 
 
0.3331 0.3582 29 
 
0.3253 0.2913 
11 
 0.3163 0.3093 
30 pre-vac 0.2995 0.2432 
12 
 
0.2942 0.2480 30 post-vac 0.3044 0.2317 
13 infected  0.3416 0.3667 31 pre-vac 0.2864 0.2278 
14 
 
0.2983 0.2967 31 post-vac 0.3187 0.2516 
15 infected  0.3287 0.3191 32 pre-vac 0.2995 0.2544 
16 
 
0.2756 0.2997 32 post-vac 0.3070 0.2522 
17 
 0.2976 0.2858 
33 pre-vac 0.2827 0.2547 
18 
 
0.2637 0.3074 33 post-vac 0.2978 0.2468 
19 
 0.3162 0.2886 
34 pre-vac 0.3097 0.3121 
20 pre-vac 0.2676 0.2490 34 post-vac 0.3114 0.3186 
20 post-vac 0.3467 0.3321 35 pre-vac 0.2686 0.2859 
21 
 
0.3067 0.2761 35 post-vac 0.3273 0.2434 
22 pre-vac 0.2475 0.2878 36  0.3099 0.2478 
22 post-vac 0.3353 0.2391 NC 
 
0.043 0.045 
Pre-vac: before booster this season; post-vac: after booster this season; NC: control assay 
 
 
 
3.4.1.4 ELISA results for sera from stud S 
 
1/10 diluted sera from stud S were used for ELISA study. It is clear that all of the 
sera from Stud S showed antibody responses to all three SeM peptides (Table 
3.13). 
 
OD values of sera from infected horse (SI-10) were similar to those from other 
horses against all three peptides. 
 
After vaccination, the OD values of sera from horse SI 11 showed slight decrease 
against all three peptides. 
 
Although horse SI-20 was vaccinated 2 years ago, the OD values of its sera 
against all three peptides were comparable with the others. 
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Table 3.13 ELISA Results for Sera from Stud S 
  
OD values against SeM 99 
peptide 
OD values against SeM 
100 peptide 
OD values against 
SeM vac peptide 
horse No. status OD-1 OD-2 OD-1 OD-2 OD-1 OD-2 
SI-1 
 
0.2850 0.2967 0.3308 0.2308 0.3051 0.2491 
SI-2 
 0.2995 0.3652 0.2994 0.2771 0.2954 0.3031 
SI-3 
 
0.2773 0.4539 0.3190 0.3450 0.3362 0.3532 
SI-4 
 0.2933 0.4076 0.3080 0.3403 0.3296 0.3196 
SI-5 
 
0.3293 0.3726 0.3143 0.2982 0.3090 0.2663 
SI-6 
 0.2663 0.2787 0.3323 0.2873 0.2949 0.2175 
SI-7 
 0.3314 0.2910 0.3630 0.3519 0.3425 0.2149 
SI-8 
 
0.2892 0.2913 0.3320 0.2718 0.3135 0.2345 
SI-9 
 0.2616 0.3322 0.3140 0.2485 0.2931 0.2536 
SI-10 
infected with S. equi 
strain 100 0.2797 0.4271 0.2945 0.3038 0.3077 0.2619 
SI-11 
 
0.3362 0.4139 0.3210 0.4051 0.3208 0.4686 
SI-12 
 0.2781 0.3954 0.2944 0.3320 0.3237 0.2959 
SI-13 
 
0.2581 0.4015 0.2908 0.2555 0.2952 0.2360 
SI-14 
 0.2500 0.3470 0.2919 0.2730 0.3028 0.2589 
SI-15 
 0.2621 0.2527 0.3125 0.2302 0.2846 0.2193 
SI-16 
 0.3019 0.2851 0.3133 0.2593 0.2740 0.2331 
SI-17 
 0.2768 0.3863 0.3091 0.3415 0.3796 0.3870 
SI-18 
 
0.2967 0.3400 0.3087 0.2615 0.3146 0.3094 
SI-19 
 0.2822 0.3559 0.3029 0.2671 0.3166 0.3959 
SI-20 
Vaccinated with 
Equivac 2in1 on 
16/11/2010 0.2789 0.2842 0.2915 0.2594 0.3044 0.2715 
NC 
 
0.041 0.042 0.046 0.040 0.045 0.042 
 
 
 
3.4.2 ELISA Results for PEPK Peptide 
 
3.4.2.1 ELISA results for sera from stud W 
 
1/10 diluted sera from stud W were used for ELISA study. It is clear that all of the 
sera from Stud W showed strong reaction with the PEPK peptide and the serum 
antibody responses of individual horses to the PEPK peptide were relatively 
variable (Table 3.14). Their OD values ranged from 0.234 to 0.642.  
 
After vaccination with Equivac S, the ODs of the sera from 9 horses had slight 
increase (horses A, F, P, R, S, T, X, Y, AA). The OD values of the sera from 
horse L had a relatively high increase. In contrast, the sera from 8 horses showed 
slightly decreased OD values (horses C, D, E, G, K, M, O, and V). 
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Table 3.14 ELISA results for sera from stud W against PEPK peptide 
 
 
 
3.4.2.2 ELISA results for sera from stud A 
 
1/10 diluted sera from stud A were used for ELISA study. It is clear that all of the 
sera from Stud A showed strong reaction with the PEPK peptide and the serum 
antibody responses of individual horses to the PEPK peptide were relative 
variable. Most of the sera from stud A had relative high serological reactivity to 
the PEPK peptide, with ODs >0.5. 
 
Only the ODs of serum from horse 34 had a marked increase after vaccination.  
 
The OD values of the sera from the four infected horses did not differ much with 
the ODs of the sera from the uninfected horses. 
 
The OD values of the sera from two horses had a slight increase after vaccination 
(horses 31 and 32). In contrast, the OD values of the sera from three horses 
decreased after vaccination (horses 28, 30, and 35).   
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Table 3.15 ELISA results for sera from stud A against PEPK peptide 
 
 
 
 
 
3.4.2.3 ELISA Results for sera from Stud S 
 
1/10 diluted sera from stud S were used for ELISA study. All of the sera from 
Stud S showed serological reactivity against the PEPK peptide. The serum 
antibody responses of individual horses from the South Island to the PEPK 
peptide were very variable.  
 
The OD of the serum from Precious Maiden nearly doubled after vaccination with 
Strepvac 2in1.  
 
The ODs of the serum from the infected horse (SI-10) was similar to other horses.  
Although horse SI-19 was vaccinated nearly 2 years ago, the OD values of its 
serum were still very high.  
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Table 3.16 ELISA results for sera from stud S against PEPK peptide 
 
 
 
 
3.4.2.4 ELISA results for sera from stud O 
 
1/10 diluted sera from stud O were used for ELISA study. All of the sera from 
Stud O showed serological reactivity against the PEPK peptide. The serum 
antibody responses of individual horses to the PEPK peptide were variable. 
 
After vaccination, the OD values of sera from horses 36 and 39 slightly increased. 
Whereas, the OD values of sera from horses 37 and 40 had a slight decrease. 
 
Most of the other post-vaccinated sera showed relatively high OD values except 
that of horse 43.  
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Table 3.17 ELISA results for sera from stud O against PEPK peptide 
 
 
 
 
 
3.5 Vaccine Potency 
 
Four sera were used to test the complement mediated antibody bactericidal assay. 
The number of colonies on blood agar plates did not differ much between 
treatment groups and control groups. 
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Chapter Four 
 
Discussion 
 
4.1 Background 
 
S. equi is the causative agent of strangles. S. equi infects horses through the nose 
or mouth. However it does not colonize the nasopharynx and is often not detected 
in nasopharyngeal swabs or washes taken 24 hours post-infection (Taylor et al., 
2006). Moreover, S. equi does not persist in the tonsils and it rarely infects 
animals other than horses. Critical to the global success of S. equi is its ability to 
establish persistent infections within the guttural pouches of recovered apparently 
healthy horses that can result in transmission to in-contact animals (Waller and 
Jolley, 2007). 
 
After recovery from strangles, most of the horses can form a strong and long-
lasting immunity (Todd, 1910; Hamlen et al., 1994). This induced immunity can 
prevent horses from infection by the same strain of S. equi for at least 5 years 
(Todd, 1910; Hamlen et al., 1994). During convalescence, the horse’s immune 
system produces a strong serum IgGb response against exposed surface proteins, 
including SeM, Se44.2, Se46.8, Se45.5 and Se42.0 (Timoney, 2004). Moreover, 
many horses can mount an opsonophagocytic serum IgGb-specific response for 
the highly antiphagocytic and immunogenic SeM at the late convalescence stage 
(Timoney, 1985). In addition, SeM-specific mucosal IgA and IgGb are induced 
during the acute and convalescent phases but not after intramuscular vaccination. 
 
Disease control or elimination requires the induction of protective immunity in a 
sufficiently high proportion of the population. This is best achieved by 
immunization programs capable of inducing long-term protection, a hallmark of 
adaptative immunity that contrasts with the rapid but short-lasting innate immune 
response. Long-term immunity is conferred by the maintenance of antigen-
specific immune effectors and/or by the induction of immune memory cells that 
may be efficiently and rapidly reactivated into immune effectors in the event of 
pathogen exposure. 
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A vaccine is a biological preparation that improves immunity to a particular 
disease. Vaccines act via processes of inducible immunity and immune memory 
(Delves et al., 2011). Memory B-cells are crucial for vaccine-mediated protection. 
Contact with pathogen stimulates B-cells to proliferate and differentiate to 
produce copious amounts of antibody (Delves et al., 2011). Equally, the contact of 
memory B-cells with the pathogen is important as it boosts plasma-cell numbers 
and serum-antibody concentrations for the next encounter with the pathogen. The 
predominant role of B cells in the efficacy of current vaccines should not 
overshadow the importance of T cell responses: T cells are essential to the 
induction of high-affinity antibodies and immune memory, and novel vaccine 
targets have been identified against which T cells are likely to be the prime 
effectors (Delves et al., 2011). 
 
Previous research has established that fourteen or more surface-exposed or -
secreted proteins of S. equi (Table. 4.1) can elicit strong serum antibody responses 
during infection and convalescence (Sweeney et al., 2005). Furthermore, there are 
a number of immunoglobulin binding proteins present in S. equi. 
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Table 4.1 Surface-exposed or secreted proteins of S. equi which can elicit strong serum 
antibody responses during infection and convalescence. Their homologs from S. 
zooepidemicus were also shown. Sequence similarities between proteins of S. equi and their 
homologs in S. zooepidemicus were examined using the BLAST tool (NCBI). 
Proteins of S. equi Homologs in S. 
zooepidemicus 
Sequence similarities 
SeM (M like protein) SzM 67% to 71% 
SeeH (superantigen) No  
SeeI (superantigen) No  
SeeL (superantigen) No  
SeeM (superantigen) No  
Se18.9 (H factor binding protein) No  
EAG (Ig, alpha2-macroglobulin and 
albumin binding protein) 
ZAG 95% to 99% 
CNE (collagen binding protein) CNZ 89% 
SclC (collagen-like surface-anchored 
protein) 
SclC 46% to 89% 
FNE (fibronectin-binding protein) FNZ 49% 
SFS (fibronectin-binding protein)  SFS-like protein 81% to 87% 
FNEB (fibronectin-binding protein) FNZ2 76% to 77% 
IdeE (IgG endopeptidase) IdeZ 99% 
IdeE2 (IgG endopeptidase) IdeZ2 70% 
 
 
4.2 Western Blotting 
 
Western blotting is a well established analytical technique used to detect specific 
proteins in a given sample. A previous study examined a series of isolates of S. 
equi from the United States and Europe by western blotting (Galan and Timoney, 
1988). Instead of using sera, mucosal nasopharyngeal mucus containing secreted 
IgG and IgA from a convalescent horse was used to react with the acid extracts of 
S. equi. Western blotting of the acid extracts from different S. equi isolates 
showed no difference when tested with nasopharyngeal mucus from a 
convalescent horse. However, they did not carry out western blotting of acid 
extracts with sera from non-infected horses or post-vaccinated horses. In this 
study, western blotting was used to detect antibodies within different sera samples 
against proteins extracted from the three S. equi strains found in New Zealand.  
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A control experiment without any horse serum was carried out to determine if 
there was any non-specific binding between the 1/5000 diluted anti-horse IgG 
HRP conjugate and S. equi proteins (Fig. 3.2).  The results showed that five bands 
(size 26 kDa, 27 kDa, 37 kDa, 49 kDa and 62 kDa) can be seen to react with 
extracts from all three strains in the control experiment, indicating the non-
specific binding of anti-horse IgG HRP to proteins from these three S. equi strains.  
 
Additional bands showed up in western blotting using pre-vaccinated horse serum 
from stud O (Fig. 3.3). Three more bands (size 34 kDa, 35 kDa, and 50 kDa) were 
seen on the membrane when using proteins from S. equi strains 99 and 100 at an 
antibody titre of 1:100. Four more bands (size 34 kDa, 35 kDa, 50 kDa, and 55 
kDa) were seen on the membrane when using proteins from S. equi vaccine strain 
(strain 2).  Those bands indicate serological reactivity between ‘natural 
antibodies’ within horse serum and proteins from the three S. equi strains. These 
‘natural antibodies’ may have been induced by previous exposure to the closely 
related S. zooepidemicus. 
 
When using Pinnacle post-vaccinated serum (at titre of 1:1000) from stud O for 
western blotting, only one more band was detected on the membrane (size 33 kDa) 
for the vaccine strain (Fig. 3.4). There was no difference of banding patterns 
between strains 99 and 100. There were two band differences between the vaccine 
strain and strain 99 or strain 100. The molecular weights of these two proteins are 
31 kDa and 55 kDa.  Thus, there was little difference observed in the western 
blotting between pre- and post-Pinnacle vaccination. This may be because the 
Pinnacle vaccine strain is a live intra-nasal vaccine and is thought to mainly 
induce secretary antibodies (primarily IgA).   
 
When using serum (at titre of 1:1000) from a horse (stud W) post-vaccinated with 
Equivac S for western blotting, although the results were not clear, the pattern of 
banding on the membrane was similar to the results seen when using Pinnacle 
vaccinated serum (Fig. 3.5). 
  
There was a dramatic difference seen in the western blotting that compared sera 
from infected horses with vaccinated horses (Fig. 3.6 and 3.7). Significantly more 
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bands and stronger interactions can be seen when using sera from the two infected 
horses at titre of 1:1000. This is because after infection the whole immune system 
(both humoral and cell-mediated) was stimulated.  
 
 
4.3 Indirect Fluorescent-antibody Assay 
 
The observation of western blotting bands in the pre-immune sera of horses plus 
the known immunoglobulin binding proteins of S. equi made the development of a 
highly specific ELISA assay difficult if not impossble. Thus, an IFA assay was 
developed. 
 
IFA is a widely used method for disease diagnosis, e.g. for tularaemia, spirochetal 
meningitis and cat scratch disease (Tsuneoka et al., 2004; Porsch-Ozcurumez et 
al., 2004). A fluorescence seen under the fluorescent microscope indicates the 
presence of antibodies within a serum sample. Moreover, the observed intensity of 
fluorescence is directly proportional to the level of antibodies against the disease. 
However the serological diagnosis of S. equi can be complicated because of the 
close relationship between it and S. zooepidemicus. DNA sequencing of the S. 
equi genome has established that S. equi evolved from S. zooepidemicus with 
which it shares 98% DNA sequence similarity. Because of 80% protein homology 
that exists between S. equi and S. zooepidemicus it would not be unexpected to 
observe serological cross-reactivity between these two organisms. Of course, 
similarity in protein sequence does not necessarily translate into similar antigenic 
epitopes, but nevertheless the possibility cannot be ignored.  
 
Until now, there has not been any research on the possibility of serological 
diagnosis of S. equi by IFA, but this technique has been used with Streptcoccus 
pyogenes (Glurich, 1991). In this study, IFA was used to detect titred antibodies 
within the sera against the three S. equi strains found in NZ to address the 
diagnosis ability of IFA and also the efficacy of those two S. equi vaccines in 
inducing antibody responses. 
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Although the IFA results were variable between horses from stud O, after 
vaccination all of their sera showed an increase in the titre of specific antibodies 
against all three S. equi strains tested. Pre-vaccinated sera from stud O had little 
serological reactivity (i.e. low fluorescent intensity) against all three S. equi 
strains at titre of 1/100, whereas all of the post-vaccinated sera showed strong 
immunological fluorescent staining to all three strains of  S. equi at titre of 1/1000. 
Antibody responses to S. equi using sera from pre-vaccinated foals at tire of 1:10 
may be from the cross-reactivity of ‘natural antibodies’ within their sera. These 
‘natural antibodies’ may have been induced by previous exposure to the closely 
related S. zooepidemicus. 
  
 
Most of the studied horses were vaccinated regularly. Their sera showed relative 
strong immunological responses to all three S. equi examined. Interestingly, there 
was not much increase of the serological reactivity against all three S. equi strains 
examined after the annual booster with Pinnacle or Equivac S this season, 
suggesting the antibodies induced by both vaccines can last longer than one year 
and may have plateaued. For example, horse SI-20 from stud S was vaccinated 
with Equivac 2in1 two years before sampling, its serum still presented 
immunological reactivity comparable with other vaccinated sera to all three S. 
equi strains at titre of 1/1000, indicating the antibody within the serum could last 
longer than two years after vaccination with Equivac S.   
 
There was little difference in vaccine titre for the IFA results between the horses 
vaccinated with Pinnacle and horses vaccinated with Equivac S. IFA results 
showed that specific antibodies were induced after vaccination with either vaccine. 
This indicates that the efficacy of both vaccines is similar against these three S. 
equi strains.  
 
Moreover, although the IFA results were variable between horses, sera from all 
vaccinated horses showed similar serological reactivity to all three S. equi strains, 
which means the induced antibodies can cross-react with these two NZ S. equi 
strains. 
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IFA results showed that those horses infected with NZ S. equi strains had specific 
antibodies within their sera against S. equi. This result is consistent with previous 
studies. In addition, the sera from infected horses showed similar fluorescent 
intensity to all three S. equi strains tested, indicating the cross-reactivity to all 
three S. equi strains. 
 
The IFA results for the sera from vaccinated horses and infected horses were 
similar, indicating the induced antibodies levels after vaccination were 
comparable to that of infected horses.    
 
 
4.4 ELISA for Three Strain Specific SeM Peptides 
 
ELISA is a plate-based assay designed for detecting and quantifying substances 
such as peptides, proteins, antibodies and hormones by using enzyme conjugated 
specific antibodies. The most reactive and best studied protein of S. equi is SeM, a 
major virulence factor and protective immunogen. The first commercially 
available ELISA kit measures a SeM specific antibody (Timoney, 2004). It is 
useful for diagnosing recent (but not necessarily current) S. equi infection, 
determining the need for booster vaccination, and as an aid in the diagnosis of 
purpura hemorrhagica and metastatic abscesses. However it cannot distinguish 
between the vaccine and infection response. Comparison of titres obtained from 
sequential samples may provide an indication of exposure and infection status. 
Serum titres peak about five weeks after exposure and remain high for at least six 
months. Responses to commercial extract vaccines peak at about two weeks and 
remain high for six months. Considerable variation in the responses of individual 
horses should be kept in mind when interpreting results of measurement of SeM 
specific antibody. Horses at risk for development of purpura are hyperresponders 
and exhibit very strong antibody responses. Such animals, with titres in excess of 
1:3200, should never be vaccinated (Timoney, 2004). 
 
However, one study (Hobo et al., 2006) found that there were non-specific 
reactions to SeM in the sera from horses infected with S. zooepidemicus. This is 
because S. zooepidemicus also has a M like protein – SzM, which has at least 92% 
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DNA sequence similarity to SeM of S. equi.  Moreover, it is widely believed that 
S. equi evolved from S. zooepidemicus and they have 98% sequence similarity. 
Therefore, the conventionally used serodiagnostic assay for strangles has 
difficulty in distinguishing horses infected with S. equi from horses infected with 
S. zooepidemicus because of similarities in the configuration of the antigen. 
  
A BLAST search (Fig. 4.1) revealed that SzM lacks the variable N-terminal 
region which is present in the sequence of S. equi and which is used for SeM 
typing. Therefore peptide from this variable region could be used for an ELISA 
study instead of the entire SeM protein since it is absent from SzM of S. 
zooepidemicus. Three peptides targeting the N-terminal variable regions of S. equi 
strains 99, 100 and the vaccine strain were synthesized by GenScript and used in 
this study. The results from the SeM ELISA showed that the antibody responses 
of individual horses to these three SeM peptides were relative variable.  All of the 
sera from regularly vaccinated horses were reactive to all three SeM peptides 
compared with the control (OD < 0.05), but there was little difference in OD 
between the three strains or between annually boosted/vaccinated horses. This 
result is consistent with the IFA result, showing that adequate antibody titres 
existed within the sera before the annual booster. Also, the induced antibodies 
demonstrated cross-reactivity against all three S. equi strains.  
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Figure 4.1 BLAST result of SeM gene from S. equi 4047. The first three sequences 
are the SeM gene sequences from three different S. equi strains. Sequences four to 
twelve are the SzM gene sequences from different strains of S. zooepidemicus. 
 
 
Interestingly, the OD values of the sera from post-vaccinated horses of stud O 
(Pinnacle vaccine) showed only a minor increase compared with the OD values of 
their sera before vaccination. The sera from pre-vaccinated foals of stud O already 
had relative strong reactions with all three SeM peptides. This result was 
inconsistent with the IFA result. This may be because of the non-specific binding 
of ‘natural antibodies’ within pre-vaccinated horse sera to SeM peptides or those 
foals may have been exposed to S. zooepidemicus.  
 
The ELISA results for naturally infected horses showed that they had specific 
antibodies against all three SeM peptides, but their ODs were not elevated 
compared to vaccinated horses. The sera from infected horses showed similar 
immunological responses to all three SeM peptides, showing that antibodies 
within infected horses sera could cross-react with all three SeM peptides tested. 
 
 
4.5 ELISA for PEPK Peptide 
 
SzPSe, the second M-like protein of S. equi, is clearly an allele of SzP, the 
protective M-like protein and typing antigen of S. zooepidemicus, and is only 
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distantly related to SeM. Although antisera to SzP and SzPSe are strongly cross-
reactive, SzP antibodies are not protective against S. equi (Hobo et al., 2006). The 
PEPK repeats region is not only present in the N-terminal region of SzPSe of S. 
equi but also in the SzP protein of S. zooepidemicus. It is also known that the 
number of repeats differs between in different bacterial strains. Nevertheless, the 
horses infected with S. zooepidemicus did not have antibodies to the PEPK repeats 
antigen, whereas the horses infected with S. equi did (Hobo et al., 2006).  
 
Hobo and colleagues (Hobo et al., 2008) find that the peptide with five PEPK 
repetitions synthesized from the C-terminal PEPK repeats area of SzPSe reacted 
most strongly with the sera from the horses infected experimentally with S. equi 
and the horses convalescing from strangles, and reacted only minimally with the 
sera from the horses infected experimentally with S. zooepidemicus and the 
control horses. In the ELISA the OD of the sera from the horses infected with S. 
equi was significantly higher than the OD of the sera from the horses infected 
with S. zooepidemicus or the control horses.  However, they did not study the 
effect of vaccination for strangles. 
 
In this study, the value of this ELISA to those vaccinated horses, as well as 
infected horses was evaluated. It is clear that all sera had serological reactivity to 
the PEPK peptide. In general, the PEPK peptide had higher OD values than SeM 
peptides, indicating more antibodies against PEPK peptide existed within the sera 
than against the SeM peptides.  
 
All of the sera from regularly vaccinated horses showed stronger reactivity to the 
PEPK peptide compared with the control, but there was little difference in OD 
between pre- and post-vaccinated horses. This result is consistent with the ELISA 
result for SeM peptides, showing adequate antibodies still existed within the sera 
before the annual booster. 
 
Similar to the ELISA results for SeM peptides, the OD values of the sera from 
post-vaccinated horses of stud O had only very minor increases compared with the 
OD values of their sera before vaccination. This also might be from the non-
specific binding of ‘natural antibodies’ within pre-vaccinated horse sera to PEPK 
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peptide. These ‘natural antibodies’ may have been induced by previous exposure 
to the closely related S. zooepidemicus. 
  
 
ELISA results showed that infected horses had specific antibodies against PEPK 
peptide. Also, the sera from infected horses showed similar immunological 
responses to PEPK peptide. Moreover, the ODs of the sera from infected horses 
were similar to the OD values of the sera from vaccinated horses, indicating that 
the antibodies induced by vaccines were comparable with the antibodies within 
infected horses.   
 
While the Hobo et al. (2006, 2008) studies suggested that the PEPK peptide could 
be useful in diagnosis of S. equi infection, I found that the PEPK peptide was not 
suitable for diagnosis of strangles due to cross-reactivity. 
 
 
4.6 Complement Mediated Bactericidal Assay 
 
Complement mediated bactericidal assay is one of the defence arms of acquired 
immunity against bacterial infections (Taylor, 1992). Predictions of the 
protectiveness of vaccine-induced immune sera have been assessed by 
complement mediated bacterial killing assay and phagocytosis assays (Ayalew et 
al., 2012). The bactericidal assay has many forms, but generally, it includes the 
incubation of bacterial cells, serum, and a complement source for a certain period 
of time and quantifying bacterial cell death in some fashion (Ayalew et al., 2012).  
 
In this study, guinea pig complement was used for bactericidal assay. The assay 
carried out in this study is modified from Ayalew and colleagues (Ayalew et al., 
2012). The results showed that sera from post-vaccinated horses or infected horses 
did not demonstrate any bactericidal ability against any of the three S. equi strains 
examined.  
 
 
4.7 Conclusion 
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From the results of western blotting, IFA and ELISA, it is clear that the post-
vaccinated horses had high levels of pre-existing antibodies within their sera to all 
three S. equi strains examined, even one year after vaccination. One sample 
showed high level of antibodies two years after vaccination. This may suggest that 
an increase in the interval of booster time could be acceptable. However, it is 
acknowledged that antibody titres do not necessarily equal protection from 
infection. In addition, the induced antibodies levels observed after vaccination by 
either Pinnacle or Equivac S are similar, showing the comparable efficacy of these 
two vaccines. Moreover, western blotting results showed that infected horses 
formed a stronger immunity than post-vaccinated horses.  This is because after 
infection the whole immune system will be stimulated (both humoral and cell-
mediated). 
 
IFA results showed that antibodies induced after vaccination or infection had 
similar immunological reactivity to those three S. equi strains tested. Also my 
ELISA results showed that the antibody responses to those three strain-specific 
SeM peptides are similar. There was no difference between pre- and post-
vaccinated horses. Those results indicate that the antibodies within sera are 
general and could cross-react with different strains.  
 
Compared to the ELISA results, the IFA results showed a difference in titre 
between pre-vaccinated horses and post-vaccinated horses. Hence, IFA is a better 
method to both diagnose strangles and to study the antibody responses after 
vaccination or infection. Although non-specific binding could complicate the 
results of IFA, a higher intensity of fluorescence can be seen after vaccination or 
infection.   
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Appendices 
 
Appendix I INFORMATION OF HORSES USED IN THIS 
STUDY 
 
 
Table AI.1 Information of horses from stud S 
Horse No. Date of 
bloods 
received 
Date of 
bloods taken 
Notes 
SI-1 17/09/12 13/09/12 Bloods were taken 
before StrepVac 
2in1 vaccination. 
Mares have been 
exposed to strangles 
during outbreak 
SI-2 17/09/12 13/09/12 
SI-3 17/09/12 13/09/12 
SI-4 17/09/12 13/09/12 
SI-5 17/09/12 13/09/12 
SI-6 17/09/12 13/09/12 
SI-7 17/09/12 13/09/12 
SI-8 17/09/12 13/09/12 
SI-9 17/09/12 13/09/12 Never exposed to 
strangles 
SI-10 20/09/12  Infected with 
strangles 
SI-11 27/09/12 25/9/12 Blood taken prior to 
strepvac 2in1 
vaccination. 
Received pinnacle 
last season 
SI-12 27/09/12 25/9/12 Vaccinated with 
strepvac 2in1 
25/09/12 
Bloods taken before 
strepvac 2in1 
vaccination 
SI-13 27/09/12 25/9/12 
SI-14 27/09/12 25/9/12 
SI-15 27/09/12 25/9/12 
SI-16 27/09/12 25/9/12 
SI-17 
 
15/10/12 
15/10/12 
 Mares were 
vaccinated with 
pinnacle 2011/2012 
season and boosted 
with strepvac 2in1 
10/10/12 
SI-18 15/10/12  Vaccinated with 
strepvac 2in1 
16/11/10 
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Table AI.2 Information of horses from stud W 
Horse 
name 
Age 1st BT 2nd BT 2011 
vaccination 
notes 
A 13 16/10/12 20/11/12 05/09/11  
B 13 16/10/12 20/11/12 02/09/11  
C 8 31/08/12 09/10/12 17/09/11  
D 8 16/10/12 20/11/12 08/11/11  
E 10 31/08/12 09/10/12 20/10/11  
F 17 31/08/12 09/10/12 01/08/11  
G 9 16/10/12 26/11/12 21/09/11  
H 7 31/08/12 09/10/12 24/11/11  
I 13 31/08/12 09/10/12 23/09/11  
J 11 31/08/12 09/10/12   
K 4 26/11/12    
L 13 16/10/12 20/11/12 10/09/11  
M 15 31/08/12 09/10/12   
N 17 16/10/12 26/11/12   
O 4 31/08/12 09/10/12   
P 5 31/08/12 09/10/12   
Q 11 31/08/12 09/10/12 28/09/11  
R 14 31/08/12 09/10/12 12/11/11  
S 20 24/10/12 28/11/12   
T 11 31/08/12 09/10/12 17/09/11  
U 6 31/08/12 09/10/12 17/09/11  
V 8 16/10/12 26/11/12 20/10/11  
W 13 31/08/12 09/10/12 30/07/11  
X 11 31/08/12 09/10/12   
Y 23 26/11/12  16/09/11  
Z 14 24/10/12 28/11/12   
AA 16 16/10/12 20/11/12 23/09/11  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 68 
 
 
Table AI.3. Information of horses from stud A 
Horse name Date of blood 
received  
status 
1 1/3/2013  
2 1/3/2013  
3 1/3/2013  
4 1/3/2013  
5 1/3/2013 Infected 
6 1/3/2013 Infected 
7 1/3/2013  
8 1/3/2013  
9 1/3/2013  
10 1/3/2013  
11 1/3/2013  
12 1/3/2013  
13 1/3/2013 Infected 
14 1/3/2013  
15 1/3/2013 infected 
16 1/3/2013  
17 1/3/2013  
18 1/3/2013  
19 1/3/2013  
20 7/3/13 Sera were taken 
before and after 
booster this season 
21 7/3/13 
22 7/3/13 
23 7/3/13 
24 7/3/13 
25 12/3/13 
26 12/3/13 
27 12/3/13 
28 12/3/13 
29 12/3/13 
30 12/3/13 
31 19/3/13 
32 19/3/13 
33 19/3/13 
34 19/3/13 
35 19/3/13 
36 30/4/13 
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Table AI.4. Information of horses from stud O 
Horse No. Date of foal 
born 
Date of blood 
received 
Notes 
36 03/11/12 8/4/13 Mare boosted 
for strangles 
27/04/12 with 
Pinnacle. Sera 
were taken 
before and after 
vaccination 
 
37 15/09/12 
38  24/09/12 
39 06/11/12 
40  18/09/12 30/4/13 Mare boosted 
for strangles 
27/04/12 with 
Pinnacle. Sera 
were received 
after vaccination 
41  
42  
43  
44  
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